[COMPANY_004]  Consumer Healthcare  
Clinical Protocol  
Protocol Number : [ADDRESS_668] Dentifrice Control When Used Twice Daily 
for 8 Weeks  
Protocol Number:  300024  
Compound/Product Name:  [CONTACT_1215] (US) Investigational 
New Drug (IND) Number:  N/A 
European Clinical Trials Database 
(EudraCT) Number:  N/A 
Other Regulatory Agency Identified 
Number:  N/A 
Phase:  N/A 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
This document contains confidentiality statements that are not relevant for this publicly
available version
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 2 of 63 
 
Sponsor Information  
 
Sponsor Name & Legal 
Registered Address  
 GlaxoSmithKline Consumer Healthcare 
([LOCATION_006]) Trading Limited  
[ADDRESS_669],  
Middlesex,  
TW8 9GS,  
[LOCATION_008] ([LOCATION_006])  
Sponsor Contact [CONTACT_1105] 
([COMPANY_004] CH)  
[ADDRESS_670], Warren, NJ, [LOCATION_003]  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 3 of 63 
Document History  
 
Document  Version  Summary of Changes  
Original protocol  1.0 Not applicable (N/A)  
Amendment 1  2.0 Section 9.2.3: Change from performing [ADDRESS_671] of 
country health authorities, institutional review boards/ethics committees ( IRBs/ECs), etc.   
 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 4 of 63 
Principal Investigator [INVESTIGATOR_1061]  
• I confirm agreement to  conduct the study in compliance with the protocol and any 
amendments according to the current International Conference on Harmonisation Good 
Clinical Practice (ICH GCP) guidelines.  
• I acknowledge that I am responsible for overall study conduct. I agree to personally 
conduct or supervise the described study.  
• I agree to ensure that all associates, colleagues and employees assisting in the conduct of 
the study are informed about their obligations. Mechanisms are in place to ensure site staff 
receives all appro priate information throughout the study.  
• I agree to conduct this study in full conformance with the laws and regulations of the 
country in which the research is conducted and the Declaration of Helsinki.  
 
Investigator Name:   
[CONTACT_1216]:   
Investigator Signature:   
[CONTACT_1217]/Agreement:  
DD-Mmm -YYYY  
 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 5 of 63 
Table of Contents  
Sponsor Information  ................................ ................................ ................................ ............  2 
Document History  ................................ ................................ ................................ ...............  3 
Principal Investigator [INVESTIGATOR_1061]  ................................ ................................  4 
Table of Contents  ................................ ................................ ................................ ................  5 
1 PROTOCOL SUMMARY  ................................ ................................ ................................  10 
1.1 Synopsis  ................................ ................................ ................................ .................  10 
1.2 Schedule of Activities  ................................ ................................ ............................  13 
2 INTRODUCTION  ................................ ................................ ................................ .............  14 
2.1 Study Rationale  ................................ ................................ ................................ ...... 14 
2.2 Background  ................................ ................................ ................................ ............  14 
2.3 Benefit/Risk Assessment  ................................ ................................ .......................  15 
2.4 Mechanism of Action/Indication  ................................ ................................ ...........  [ADDRESS_672] Restrictions  ................................ ...............................  23 
5.5.5  Medication and Treatment Restrictions  ................................ ................  23 
5.5.6  Contraception  ................................ ................................ ........................  23 
5.6 Screen Failures ................................ ................................ ................................ ....... 23 
5.7 Sponsor’s Qualified Medical Personnel  ................................ ................................  24 
5.8 Clinical Examiner Qualifications  ................................ ................................ ..........  24 
6 INVESTIGATIONAL/STUDY PRODUCTS ................................ ................................ ... 24 
6.1 Investigational/Study Product Supplies  ................................ ................................ . 24 
6.1.1  Medical Devices  ................................ ................................ ....................  26 
6.1.2  Dosage Form and Packaging  ................................ ................................ . 26 
6.1.3  Preparation and Dispensing ................................ ................................ ... 26 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_673] Usage Errors  ................................ ................................ ............  27 
6.2.2  Overdose  ................................ ................................ ...............................  27 
6.3 Investigational/Study Product Storage  ................................ ................................ .. [ADDRESS_674] Accountability  ................................ ................................ ................  28 
6.4.1  Destruction of Investigational/Study Product Supplies  ........................  29 
6.5 Blinding and Allocation/Randomi zation  ................................ ...............................  29 
6.6 Breaking the Blind  ................................ ................................ ................................ . 29 
6.7 Compliance  ................................ ................................ ................................ ............  30 
6.8 Concomitant Medication/Treatment(s)  ................................ ................................ .. [ADDRESS_675] 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ .........  [ADDRESS_676] Dis continuation/Withdrawal  ................................ ................................ ..... [ADDRESS_677] to Follow up  ................................ ................................ ................................ ... 31 
8 STUDY PROCEDURE S ................................ ................................ ................................ ... 32 
8.1 Visit 1/Screening  ................................ ................................ ................................ ... 32 
8.1.1  Screening Procedures  ................................ ................................ ............  32 
8.2 Study Period  ................................ ................................ ................................ ..........  34 
8.2.1  Visit 2/Day 0 - Baseline  ................................ ................................ ........  34 
8.2.2  Visit 3/Week 4 (Day 28 ± 3)  ................................ ................................ . 34 
8.2.3  Visit 4 /Week 8 (Day 56 ± 3)  ................................ ................................  [ADDRESS_678] Examination  ................................ ................................ ..................  37 
9.1.2  OHT Examination  ................................ ................................ .................  37 
9.2 Efficacy Assessments  ................................ ................................ ............................  37 
9.2.1  Macpherson Modification of the Lobene Stain Index (MLSI)  .............  37 
9.2.2  Tooth Shade (Color) Assessment  ................................ ..........................  38 
9.2.3  VITA EasyShade Assessment  ................................ ...............................  39 
9.3 Safety and Other Assessments  ................................ ................................ ...............  39 
9.3.1  Oral Soft Tissue (OST) Examination  ................................ ....................  [ADDRESS_679] Tissue (OHT) Examination  ................................ ..................  40 
9.3.3  Pregnancy Testing  ................................ ................................ .................  40 
10 ADVERSE EVENT AND SERIOUS ADVERSE EVENTS  ................................ ...........  40 
10.1  Definition of an Adverse Event (AE)  ................................ ................................ .... 40 
10.2  Definition of a Serious Adverse Event (SAE)  ................................ .......................  41 
10.3  Time Period and Frequency for Collecting  AE and SAE Information  ..................  42 
10.4  Reporting Procedures ................................ ................................ .............................  43 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_680]/ Ethics Committee ................................ ..... [ADDRESS_681] of the Study  ................................ ................................  57 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_682] Usage Instructions Sheet  ................................ ................................ ..........  61 
15.2  ABBREVIATIONS  ................................ ................................ ...............................  62 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_683] of in text tables  and figures  
Table 1 -1 Schedule  of Activities  ................................ ................................ ...........  13 
Table 3 -1 Study Objectives and Endpoints  ................................ ...........................  16 
Table 6 -1 Investigational/Study Product Supplies  ................................ ................  25 
Table 6 -2 Sundry Items  ................................ ................................ .........................  25 
Table 12 -1 Sample Size Power by [CONTACT_1106] 5% and 2.5% Significance 
Levels with 90 Subjects per Arm  ................................ ..........................  51 
Figure 12 -1 Graphical Approach Showing Allocation and Propagation of Alpha 
Between Hypotheses Within Each Experimental Dentifrice  ................  53 
Table 15 -1 Abbreviations  ................................ ................................ ........................  62 
 
  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 10 of 63 
1 PROTOCOL SUMMARY  
1.1 Synopsis  
Background and Rationale:  
This study will investigate the efficacy  of two experimental 5% potassium nitrate  (KNO 3) 
dentifrices, one containing alumina and sodium tripolyphosphate (STP), the other alumina, STP 
and high cleaning silica, to reduce extrinsic dental stain and thereby [CONTACT_1107], compared 
to a marketed regular fluoride dentifrice with 8 weeks twice daily brushing.  
Objectives and Endpoints:  
Objectives  Endpoints  
Primary  
To evaluate the change in extrinsic dental stain after 8 weeks 
twice daily use of a ‘5% KNO 3/1% alumina/5% STP’ dentifrice, a 
‘5% KNO 3/1% alumina/ 5% STP/2% silica’ dentifrice and a 
regular fluoride dentifrice, as measured by [CONTACT_1108] (Total MLSI (Area x Intensity)).  Change from baseline in mean 
Total MLSI (Area x Intensity ) 
score at week 8 . 
Secondary  
To evalua te the change in extrinsic dental stain after 4 weeks 
twice daily use of a ‘5% KNO 3/1% alumina/5% STP’ dentifrice, a 
‘5% KNO 3/1% alumina/ 5% STP/2% silica’ dentifrice and a 
regular fluoride dentifrice, as measured by [CONTACT_1108] (Tota l MLSI (Area x Intensity)).  Change from baseline in mean 
Total MLSI (Area x Intensity ) 
score at week 4. 
To compare the change in extrinsic dental stain after 4  & 8 
weeks twice daily use of either a ‘5% KNO 3/1% alumina/5% 
STP’ dentifrice or a ‘5% KNO 3/1% alumina/ 5% STP/2% silica’ 
dentifrice, compared to a regular fluoride dentifrice, as 
measured by [CONTACT_1109] (A rea x Intensity ). Change from baseline in mean 
Total MLSI (Area x Intensity ) 
score at week s 4 & 8.  
To evaluate and compare the change in tooth sh ade (color) 
after 4 and 8 weeks twice daily use of either a ‘5% KNO 3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO 3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured by [CONTACT_1110] 3D -
MASTER.  Change fr om baseline in mean 
VITA shade score (examiner 
assessed) at weeks 4 & 8.  
To evaluate and compare the changes in dental stain at specific 
tooth sites (along gingival margin, inter -proximally and on the 
body of the tooth) after 4 and 8 weeks twice daily use  of either a 
‘5% KNO 3/1% alumina/5% STP’ dentifrice or a ‘5% KNO 3/1% 
alumina/ 5% STP/2% silica’ dentifrice, compared to a regular 
fluoride dentifrice, as measured by [CONTACT_1109] (A rea x 
Intensity ). Change from baseline in mean 
MLSI (Area x Intensity) in:  
• Gingival sites  
• Interproximal sites  
• Body sites  
To evaluate and compare change in extrinsic dental stain after 4 
and 8 weeks twice daily use of either a ‘5% KNO 3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO 3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured by [CONTACT_1111] (A rea) and MLSI (I ntensity ). Change from baseline in mean 
MLSI (Area) and MLSI (Intensity)  
Exploratory  
To evaluate and compare the change in tooth color co -ordinates 
after 4 and 8 weeks twice daily use of either a ‘5% KNO 3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO 3/1% alumina/ 5% Change from baseline in mean 
tooth shade, L *, a*, b*, WI D and 
ΔE* determined using the VITA 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 11 of 63 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured using the VITA EasyShade . Easy Shade instrument at weeks 
4 & 8  
Safety  
To assess the safety and tolerability of the two experimental 
KNO3 dentifrices . Treatment emergent adverse 
events  
Mean MLSI values calculated for the facial surfaces of the six maxil lary anterior teeth and 
six mandibular anterior teeth, and the lingual surfaces of the six mandibular anterior teeth . 
Mean tooth shade/color values are calculated for the facial surfaces of the 4 central and 
lateral maxillary incisors . 
Study Design:  
This will be a single -center,  8-week, randomized, controlled , single -blind (clinical examiner (s) 
and V ITA EasyShade operator), three treatment -arm, parallel design, stratified  clinical study  in 
healthy volunteers  with clinically confirmed dental stain ( originat ing from the diet  and/or  
smoking ) on the surfaces of their anterior teeth . 
Potential  subjects will attend a  screening  visit (Visit 1, Day 0) to determine their suitability to 
participate .  Having obtained their written informed consent,  relevant details of  their medical 
history and current medications will be recorded, followed by  [CONTACT_1112] ( OST ) and oral 
hard tissue ( OHT ) examinations.  Subjects meeting the relevant  study criteria , will be 
considered as eligible to proceed for baseline assessments  on the same day . 
At the baseline visit (Visit 2, Day 0), e ligible subjects will undergo  clinical and instrumental 
assessments of extrinsic dental stain (MLSI: facial surfaces of the six maxillary anterior teeth 
and six mandibular anterior teeth , and the lingual surfaces of the six mandibular anterior teeth) 
and tooth color  (VITA Bleachedguide 3D -MASTER  and VITA EasyShade  instrument : facial 
surfaces of the central and lateral maxillary incisors ). 
Qualifying subjects will be stratified by [CONTACT_1113] (A x I)  (calculated for the facial 
surfaces of the six maxillary anterior teeth and six mandibular anterior teeth  only)  and smoking 
status  and randomized to one of the three study treatments.  Randomized subjects will be 
instructed to brush twic e daily (for 2 minutes, morning and evening) with their assigned study 
dentifrice for the next 8 weeks. Extrinsic dental stain and tooth color assessments will be 
repeated after 4 - and 8 -weeks treatment.  
Study Products:  
Experimental Dentifrices  Reference  Dentifrice  
5% KNO 3 dentifrice with 
1% alumina and 5% STP  5% KNO 3 dentifrice with  
1% alumina, 5% STP and  
2% high cleaning silica  Regular Fluoride Dentifrice  
(Aquafresh Cavity Protection, 
US market)  
Each s tudy dentifrice will contain 0.2542% sodium fluoride  
(1100 parts per million (ppm) fluoride ) 
All dentifrices will be applied in the same manner and will be brushed on to the teeth, twice 
daily (morning and evening) for 2 timed minutes.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 12 of 63 
Type and Planned Number of Subjects:  
Study subjects of either sex and any gender , aged of 18 -65 years , will be in good general and 
oral health, with the level of extrinsic tooth stain and color required at baseline to participate in 
the study.  
Sufficient  subjects will be screened to randomize approximately  300 subjec ts to study treatment 
(approximately 10 0 per treatment group) to  ensure approximately 2 70 evaluable subjects 
complete the study.   
Statistical Analysis Summary : 
For the analysis of the change from baseline in the mean Total MLSI ( Area x Intensity ) and the  
change from baseline in the mean VITA shade score , separate  Mixed Models with Repeated 
Measures  will be used. Fixed effects will be included for smoking status, study product, visit 
and study product x visit interaction. The respective baseline score will be included as a 
covariate. Subject will be included as a repeated measure with unstructured covariance matrix. 
Kenward Rogers degrees of freedom approach will be applied. The least square means for each 
Experimental Dentifrice  at week [ADDRESS_684] for a differe nce between products.  
The hypothesis testing of the of change from baseline in the mean Total MLSI ( Area x Intensity ) 
and the  change from baseline in the mean VITA shade score  will employ a graphical approach 
methodology , as per Bretz et al (Bretz et al., 2009 ) in order to maintain an overall two -sided 
familywise error rate  of 5% within each Experimental Dentifrice (10% overall).  The adjusted 
two-sided p -values and simultaneous 95% confidence intervals (following graphical testing 
approach) will be provided for all comparisons.  
  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_685] visits and study procedures.   
The investigator may schedule visits (unplanned visits) in addition to those listed on the 
schedule of activities, to conduct evaluations or assessments required to protect the w ell-being 
of the subject.  
Table 1-1 Schedule of Activities   
Procedure/Assessment  Screening  Treatment Period  
Visit 1 
Screening 
(Day 0)4 Visit 2 
Baseline 
(Day 0)4  Visit 3 
Week 4  
(Day 28 ±3 
days)   Visit 4 
Week 8  
Day 56 ±3 
days)  
Informed consent  X 
 
4 Weeks   
4 Weeks   
Demographics  X    
Medical History / current oral care 
products / c urrent  and prior medication 
review  X    
Review changes in health and 
concomitant medications/treatments    X X 
OST Examination  X  X X 
OHT Examination X   X 
Clinical a ssessment of extrinsic dental 
stain ( MLSI )2  X X X 
Clinical a ssessment of tooth color  (VITA 
Bleachedguide)   X X X 
Instrumental assessment of tooth color 
(VITA EasyShade)   X X X 
Repeatability assessments3  X X X 
Inclusion/exclusion criteria  review  X X   
Subject eligibility  X X   
Subject continuance    X X 
Randomization and stratification   X   
Dispense study products, diary and 
sundry items   X X  
Supervised tooth brushing   X X  
Return of study dentifrice, toothbrush 
and completed diary    X X 
Adverse events review1  X X X 
Medical device incidents review1  X X X 
Study conclusion     X 
Abbreviations: OST: Oral Soft Tissue, OHT: Oral Hard Tissue, MLSI: Modified Lobene Stain Index  
Footnotes:  
1. Adverse Events (AEs), Serious Adverse Events (SAEs) and medical device incidents collected immediately after subject provides  
consent to participate in the study by [CONTACT_1114] (ICF)  until [ADDRESS_686] use of the study 
dentifrice (or last procedure) .  Medical device in this study is the supplied toothbrush.  
2. Brushing and/or flossing of the subject’s assessment teeth will be performed prior to this assessment b y the examiner if required (at the 
examiner’s discretion).  
3. Repeatability assessments for V ITA Bleachedguide and MLSI assessments will be performed on a subset of subjects as described in 
Section 9.  
4. Note  Visits 1 & 2 will occur on the same day.  
 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 14 of 63 
2 INTRODUCTION  
Dental stain is common within the adult population.  Extrinsic dental stain is primarily caused 
by [CONTACT_1115] (originating from the diet, smoking and medications) binding to proteinaceous 
compounds found in the salivary pellicle (Watts and Addy, 2001 , Shellis et al., 2005 ).  The 
etiology of stain is multiple, and whil e it is widely agreed to result from discoloration of plaque 
and pellicle on the surface of the tooth, the main site for extrinsic stain build up is generally 
accepted as the acquired salivary tooth pellicle (Shellis et al., 2005 ).  One of the main functions 
of a dentifrice is to help control the build -up of dental stain (Pader, 2012 ).  This is usually 
achieved by [CONTACT_1116] a common dental abrasive, such as silica, chalk or dicalcium 
phosphate d ihydrate in the dentifrice formulation (Lippert, 2013 ).  More recently alumina has 
been investigated for its enhanced stain removal and stain protection properties compared to 
silica (Milleman et a l., 2017 , Young et al., 2017 ) with low er dentine abr asivity (Seong et al., 
2017 ). 
Chemical cleaning compounds, such as polyphosphates are also commonly employed in 
dentifrices to supplement the physical cleaning provided by [CONTACT_1117].  Polyphosphates, 
such as sodium tripolyphosphate (STP), sodium  pyrophosphate and hexametaphosphate, have 
been shown to bind strongly to the tooth surface and reduce the force of adhesion of adsorbed 
proteins (Shellis et al., 2005 ), thereby [CONTACT_1118].  
Polyphosphates have also been shown to desorb salivary proteins from enamel and inhibit 
protein adsorption (Ash et al., 2014 ) and thereby [CONTACT_1119] .  
The aim of  this study is to investigate the stain removal efficacy of 2 experimental anti-dentin 
hypersensitivity (DH) dentifrices:  
• 5% potassium nitrate (KNO 3) dentifrice containing 1% alumina and 5% STP  
• 5% KNO 3 dentifrice containing 1% alumina, 5% STP and 2% high c leaning silica  
with four and eight weeks twice daily use .  A daily use, regular fluoride dentifrice (US market) 
will be included as a reference dentifrice .  
2.1 Study Rationale  
This 8-week, randomized, controlled , parallel -design, stratified  clinical study  has been designed 
to evaluate the ability of two experimental dentifrices to reduce extrinsic dental stain 
(originating from the diet  and/or  smoking ) and improve tooth color (whiten the teeth), compared 
to a regular fluoride dentifrice.   
The dental stain  removal and tooth whitening properties of 1% alumina with 5% STP has been 
demonstrated for similar dentifrice formulations ( see Section 2.2 ); additional data are required 
to confirm the stain removal/whitening effic acy of a modified 1% alumina and 5% STP 
formulation and demonstrate efficacy for a novel 1% alumina, 5% STP and 2% high cleaning 
silica formulation.   
2.2 Background  
Both experimental dentifrices contain 5% KNO 3 and 0.2542 % sodium fluoride (NaF).  The 
efficacy of KNO 3-containing dentifrices for the relief of DH (Schiff et al., 1994 , Gillam, 1996 ) 
and the anti -caries benefit associated with use of topi[INVESTIGATOR_1062] (Featherstone, 1999 , Marinho et 
al., 2003 ) are well -established.   
The sponsor has completed  four clinical studies evaluating the dental cleaning properties of 
dentifrices containing 1% alumina and 5% STP .   300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 15 of 63 
• Clinical s tudy  evaluated the ability of 4 experimental dentifrices 
(including a 1% alumina and 5% STP dentifrice ) to lighten tooth color (whiten teeth) 
compared to a regular fluoride dentifrice (Aquafresh Advanced) , after 4 weeks twice 
daily brushing.  A  statistically significant  improvement in tooth shade (1.48 units, V ITA 
Classic shade guide), versus baseline, was ob served for the 1% alumina and 5% STP 
dentifrice; there was no statistically significant difference between  any of  the test 
products and the regular fluoride dentifrice.  
• Clinical study  evaluated the stain removal efficacy of 4 experimental 
dentifrices (including a 1% alumina and 5% STP dentifrice) , compared to a regular 
fluoride dentifrice ( Aquafresh Advanced ), after 8 weeks twice daily brushing. The 1% 
alumina and 5% STP formulation demonstrated statistically significantly better stain 
removal (as measured by [CONTACT_1111]) versus  the regular fluoride dentifrice  after 8 weeks use.   
• Clinical study  found that 8 weeks’ twice daily brushing with 2 
experimental dentifrice formulations , both  containing 1% alumina and 5% STP , 
provided a statistically significant reduction of dental stain (as measured by [CONTACT_1111]) from 
baseline; no statistically significant differences were observed between the test products 
and a regular fluoride dentifrice.  
• Clinical study  evaluated the stain prevention properties of an 
experimental dentifrice  containing 1% alumina and 5% STP formulation .  The study 
demonstrated statistically significantly less stain build -up (as m easured by [CONTACT_1111]) after 
8 weeks twice -daily use, compared to a regular fluoride dentifrice.  
In all the above clinical studies, study  treatments were found to be generally well tolerated.  
In vitro  evaluation of the experimental dentifrices to be investigated  in this study has been 
performed using established models for dental stain removal (sponsor data on file) .  These 
studies show both experimental formulations to be effective at removing dental stain; the 1% 
alumina, 5% STP and 2% silica formulation (with the higher relative dentine abrasivity) 
outperforms the 1% alumina and 5% STP formulation.  
In summary, existing clinical and laboratory data provide evidence of tooth cleaning efficacy 
for 1% alumina and 5% STP dentifrice formulations.  However additional clinical ‘cleaning’ 
data is required to demonstrate dental stain removal/tooth whitening efficacy of the specific 
experimental formulations to be tested in this study to support the intended consumer claims 
for these products.  
2.3 Benefit/Risk Assessment  
Complete information  for th e experimental dentifrices may be found in the single reference 
safety document (SRSD), which for this study is the Safety S tatement.  
Whilst the exact formulations  of the experimental dentifrices under investigation have not been  
previously clinically tested, very similar products containing 5% KNO 3, 1% alumina and 5% 
STP have been evaluated in clinical studies of similar design (see Background Section 2.2 ).  
These stu dies demonstrated the efficacy and safety of similar formulations.  The active 
ingredients and formulation excipi[INVESTIGATOR_1063] a history of safe 
use in oral care products and are currently used in marketed daily use dentifric es. 
The two experimental dentifrices  are considered generally safe for topi[INVESTIGATOR_1064], with twice 
daily brushing, under the controlled conditions of a clinical trial.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI
CCI
CCI
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 16 of 63 
2.4 Mechanism of Action/Indication  
One of the main functions of a dentifrice is to help con trol the build -up of dental stain (Pader, 
2012 ). This can be achieved by [CONTACT_1120] 
(‘polishing’) of stain from tooth surface during toothbrushing and/or by [CONTACT_1121] a 
chemically active cleaning compound to the formulation.  
Polyphosphates (such as STP) are chemical clean ing compounds commonly employed in oral 
care products to supplement the physical stain removal properties of dental abrasives. 
Polyphosphates have been shown to bind strongly to the tooth surface and reduce the force of 
adhesion of adsorbed proteins (Shellis et al., 2005 ), facilitating the removal of stain during 
toothbrushing.  Polyphosphates have also been shown to desorb saliva ry proteins from enamel, 
and inhibit protein adsorption (Ash et al., 2014 ).  Combining such ‘chelating’ agents with 
effective abrasives, such as alumina and/or silica, can be more effective for the removal of 
dental stain compared to formulations with containing dental abrasive alone.  
 
3 STUDY OBJECTIVES AND ENDPOINTS  
Table 3-1 Study Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the change in extrinsic dental stain after 8 weeks 
twice daily use of a ‘5% KNO 3/1% alumina/5% STP’ dentifrice, a 
‘5% KNO 3/1% alumina/ 5% STP/2% silica’ dentifrice or a regular 
fluoride dentifrice, as measured by [CONTACT_1122] (Total MLSI (Area x Intensity)).  Change from baseline in mean 
Total MLSI (Area x Intensity ) 
score at week 8 . 
Secondary  
To evaluate the change in extrinsic dental stain after 4 weeks 
twice daily use of a ‘5% KNO 3/1% alumina/5% STP’ dentifrice, a 
‘5% KNO 3/1% alumina/ 5% STP/2 % silica’ dentifrice or a regular 
fluoride dentifrice, as measured by [CONTACT_1122] (Total MLSI (Area x Intensity)).  Change from baseline in mean 
Total MLSI (Area x Intensity ) 
score at week 4. 
To compare the change in extrinsic dental stain after 4  & 8 
weeks twice daily use of either a ‘5% KNO 3/1% alumina/5% 
STP’ dentifrice or a ‘5% KNO 3/1% alumina/ 5% STP/2% silica’ 
dentifrice, compared to a regular fluoride dentifrice, as 
measured by [CONTACT_1109] (A rea x Intensity ). Change from baseline  in mean 
Total MLSI (Area x Intensity ) 
score at week s 4 & 8.  
To evaluate and compare the change in tooth shade (color) 
after 4 and 8 weeks twice daily use of either a ‘5% KNO 3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO 3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured by [CONTACT_1110] 3D -
MASTER.  Change from baseline in mean 
VITA shade score (examiner 
assessed) at weeks 4 & 8.  
To evaluate and compare the changes in dental stain at specific 
tooth  sites (along gingival margin, inter -proximally and on the 
body of the tooth) after 4 and 8 weeks twice daily use of either a 
‘5% KNO 3/1% alumina/5% STP’ dentifrice or a ‘5% KNO 3/1% 
alumina/ 5% STP/2% silica’ dentifrice, compared to a regular 
fluoride dent ifrice, as measured by [CONTACT_1109] (A rea x 
Intensity ). Change from baseline in mean 
MLSI (Area x Intensity) in:  
• Gingival sites  
• Interproximal sites  
• Body sites  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 17 of 63 
To evaluate and compare change in extrinsic dental stain after 4 
and 8 weeks twice daily use of ei ther a ‘5% KNO 3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO 3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured by [CONTACT_1111] (A rea) and MLSI (I ntensity ). Change from baseline in mean 
MLSI (Area) and MLSI (Intensity)  
Exploratory  
To evaluate and compare the change in tooth color co -ordinates 
after 4 and 8 weeks twice daily use of either a ‘5% KNO 3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO 3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured using the VITA EasyShade.  Change from baseline in mean 
tooth shade, L *, a*, b*, WI D and 
ΔE* determined using the VITA 
Easy Shade instrument at weeks 
4 & 8  
Safety  
To assess the safety and tolerability of the two experimental 
KNO3 dentifrices . Treatment emergent adverse 
events  
Mean MLSI values calculated for the facial surfaces of the six maxillary anterior teeth and 
six mandibular anterior teeth, and the lingual surfaces of the six mandibular anterior teeth . 
Mean tooth shade/color  values are calculated for the facial surfaces of the 4 central and 
lateral maxillary incisors . 
 
This study will be considered successful if either of the experimental dentifrices demonstrates 
statistically significant stain removal (as measured by [CONTACT_1123]  (Area x Intensity ) from 
baseline after 8 weeks  twice daily use. 
4 STUDY DESIGN  
4.1 Overall Design  
This will be a single -center,  8-week, randomized, controlled , single -blind (clinical examiner(s) 
and VITA EasyShade operator), three treatment -arm, parallel design, stratified  clinical study  in 
healthy volunteers  with a propensity to form dental stain. It has been designed to investigate 
changes in tooth stain and color, following twice -daily use of two experimental dentifrices,  after 
four- and eight -week s twice daily use; a regular fluoride dentifrice will be included as reference 
dentifrice .  Sufficient subjects will be screened to randomize approximately 300 subjects to 
study treatment to ensure approximately 270 subjects complete the study.  
At screenin g (Visit 1, Day 0), subjects will give their  written informed consent  to participate in 
the study.  Demography , relevant medical history and current medications /treatments  will be 
recorded, followed by  [CONTACT_1124] .  Subjects meeting the releva nt study criteria, 
will be considered eligible to proceed  for baseline assessments on the same day .. 
At baseline (Visit 2 , Day 0 ) subjects,  having refrained from oral hygiene procedures for at least 
6 hours, will undergo clinical assessment of the stain on  the facial surfaces of the ir six maxillary 
anterior teeth and six mandibular anterior teeth (tooth numbers 6 -11 and 22 -27) and the lingual 
surfaces of the ir six mandibular anterior teeth (tooth numbers 22 -27) using the MacPherson 
modification (Macpherson et al., 2000 ) of the Lobene Stain I ndex (Lobene, 1968 ) (MLSI) . The 
shade (color) of the facial surfaces of the central and lateral maxillary incisors (tooth numbers 
7-10) will t hen be assessed clinically using the V ITA Bleachedguide 3D -MASTER  (Gómez‐
Polo et al., 2015 ) and t he color of the same surfaces will be evaluated using the VITA 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 18 of 63 
Easy Shade instrument  (Tung et al., 2002 ). Subjects who fulfil all inclusion/exclusion cr iteria 
will be enrolled into the study.  
Qualifying subjects with a Total MLSI (A x I)  15 for the facial surfaces of the 12 anterior teeth 
and a mean tooth shade  11 on the facial surfaces of the 4 maxillary incisors , who meet all 
other entry criteria, will be stratified according to their baseline Total MLSI (A x I)  (low < 45; 
high ≥ 45) and smoking status (smoker; non -smoker) and randomized to study treatment.   
Randomized subjects will brush twice daily (morning and  evening) with their assigned study 
dentifrice for the next [ADDRESS_687] each brushing in the diary provided; s ignificant 
changes in diet or smoking status should also be noted in the diary. Subjects,  having refrained 
from oral hygiene procedures for  at least 6 hours,  will return to the clinic after 4 - and 8 -weeks 
treatment (Visits 3 and 4, respectively) for c linical and instrumental assessments of dental stain  
and tooth shade/color .  
The clinical examiner will perform replicate MLSI and tooth shade a ssessments (as described 
in Sections [IP_ADDRESS]  and [IP_ADDRESS] , respectively) at Visits [ADDRESS_688]’s anterior teeth with water and/or floss between the anterior teeth prior to MLSI 
assessments, if required, to remove any debris on the teeth.  
Safety and oral tolerability of the study products will be monitored  over the 8 -week usage period 
by [CONTACT_1125].  
4.2 Scientific Rationale for Study Design  
Subjects will be stratified according to their smoking status and their baseline tooth stain score 
to ensure a balance in all treatment groups.  
A parallel group experimental design was selected as carryover effects from the treatment 
groups would be anticipated.  
According to the International Conference on Harmonisation (ICH) guidelines (ICH, Nov 2016 ), 
for a study to be classified as truly double -blind, not only does the examiner (and any 
appropriate member of staff who may be involved in the dispensing of products, analysis of 
data etc.) need to be blind to the treatm ent a subject receives, but the products under test must 
be identical in every way (color, flavor, rheology, appearance, packaging).  Given it is almost 
impossible to ensure identical appearance, taste and  packaging for the dentifrices  evaluated in 
oral ca re studies, the level of product blinding  for this study is described as  ‘examiner blind ’. 
Study dentifrices  will be supplied in overwrapped  tubes. The blind will be maintained by [CONTACT_1126], brushing instruction and  supervised brushings not being involved in the 
clinical examinations and  study products being provided to subjects in blinded packs.  
Dental examiner (s) and VITA EasyShade operator(s)  will be blind to treatment allocation to 
ensure there is no bias in the assessments.  
This is a  single -center study.  The same examiner  will perform the clinical assessments and 
instrumental measures  throughout the study to eliminate the possibility of inter -examiner 
variability.  
A regular fluoride dentifrice has been selected as  reference dentifric e.  For the purposes of this 
study, it was deemed more relevant to compare the efficacy of the experimental dentifrices 
against the stain removal/tooth whitening performance of a typi[INVESTIGATOR_1065] (which 
contains dental abrasive) rather than a p lacebo with no abrasive cleaning component.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 19 of 63 
The experimental dentifrices, when marketed, will be indicated for DH. It is anticipated they 
will be purchased by [CONTACT_1127] (less dental stain). However, 
the study objectives rela te solely to dental stain and tooth color, both of which are independent 
of DH; thus, study subjects are not specifically required to experience DH nor do the exclusion 
criteria exclude subjects with DH.  Subjects will be stratified according to their base line tooth 
stain score and smoking status to ensure balance across the three  treatment groups.  
An 8 -week treatment period is deemed sufficient to observe the anticipated clinical benefits;  4-
week assessment s are included should more rapid clinical effects occur . 
The clinical measures used in this study , MLSI and  VITA shade guide,  are well established in 
the scientific literature for the evaluation of dental stain and tooth color respectively (Joiner and  
Luo, 2017 ).  VITA shade guides are routinely used by [CONTACT_1128] (e.g. crowns, partial dentures) to 
the natural dentition.  The V ITA shade guide selected fo r use in  this study (VITA Bleachedguide 
3D-MASTER)  has the advantage over the classic VITA shade guide in providing a linear 
presentation of tooth shade which will enable more accurate assessment of shade changes  
(Paravina, 2008 ).  Furthermore, it is accepted by [CONTACT_1129] (ADA, 2020 ). 
The VITA Easy Shade instrument, whilst being a more recent approach to the assessment of  
tooth color, has been shown to provide precise measurement of tooth color in a previous clin ical 
study (Dozić et al., 2007 ) and offer s the potential for objective,  examiner -independent 
evaluation of tooth color (Knezovic Zlataric et al., 2016 ).  It is included  in this study is to 
provide further information on tooth color -specific variables (e.g. L *, a*, b*, WI D and ΔE) that 
could provide greater understanding on the tooth -cleaning properties of the experimental 
dentifrices.  
Whilst the study  products are not contra -indicated for pregnancy (their use  would not be 
expected to cause harm either to the mother or foetus ), pregnant females will be excluded from 
this study due to the increased prevalence and  severity of gingivitis and periodontal disease 
along with increased amounts of calculus and oral debris  observed with pregnancy , both of 
which could impact dental stain and tooth color  (Samant et al., 1976 ).  The severity of these 
conditions is known to vary during the course of pregnancy (Samant et al., 1977 ), thus 
pregnancy would be a confounding factor for the objectives of this study.  Pregnant females and 
those intending to become pregnant will be  excluded .  Pregnancy will be monitored by [CONTACT_1130] -
reported pregnancy status.  
4.3 Justification for Dose  
Subjects will brush with  their assigned dentifrices twice daily for 2 minutes as per  the American 
Dental Association recommendations for effective toothbrushing (ADA, 2022 ) and the [LOCATION_006] 
National Health Service teeth cleaning guide (NHS, 2019 ). 
On each brushing occasion, the toothbrush will be dosed with a ribbon of dentifrice (covering 
the entire length of the toot hbrush), in line with the proposed product labelling for the 
experimental dentifrices and the current product labelling for the marketed reference dentifrice.  
No dose modification is permitted in this study.  Any variation from the product usage 
instructio ns should be communicated to study site personnel and recorded as a deviation.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_689] visit date.  
5 STUDY POPULATION  
5.1 Type and Planned Number of Subjects  
Healthy volunteers of either sex and any gender, aged 18 – 65 years will be recr uited with 
sufficient levels of dental stain and appropriate tooth color to allow for evaluation of change 
(reduction ) in these parameters during the study.   Subjects will be recruited from the study site’s 
database.  
Sufficient subjects will be screened to  randomize approximately 3 00 subjects (equally 
distributed across the three treatment groups) to ensure approximately [ADDRESS_690] eligibility to participate in the clinical study should be reviewed and documented by [CONTACT_1131]’s study team be fore subjects are included in the study.  
5.[ADDRESS_691] meet all the following inclusion criteria to be eligible to be included into 
the study:  
1. Provision of a signed and dated informed consent document indicating that the subject has  
been informed of all pertinent aspects of the study before any assessment is performed.  
2. Subject is of either sex and any gender who, at the time of screening, is between the ages 
of [ADDRESS_692] in good general and mental health with, in the opi[INVESTIGATOR_1066], no clinically significant or relevant abnormalities  in medical 
history (for example, a medical condition confirmed to be causing xerostomia) ,or upon 
oral examination , that would impact the subject’s safety, wellbeing or the outcome s of the 
study, if they were to participate in the study, or affect the subject’s ability to understand 
and follow study procedures and requirements . 
5. Subject with generally good oral health with: 
a. At least 16 natural (vital) teeth including 11 of the 12 anterior teeth.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 21 of 63 
b. Facial surfaces of all anterior teeth (maxillary and mandibular) and lingual surfaces 
of anterior teeth (mandibular only) gradable for MLSI with no significant calculus 
or large restorations as judged by [CONTACT_1132] . 
c. Presence of extrinsic dental s tain (formed on the surface of the te eth) which , in the 
opi[INVESTIGATOR_1067], originat es from the diet  and/or use of tobacco 
products.  
d. Facial surfaces of central and lateral maxillary incisors  gradable for tooth shade ( free 
of cervical margin defects and restorations which could impact  assessment), as 
judged by [CONTACT_1132] .  
e. Baseline Total MLSI (A x I)  15 for the facial surfaces of the  12 anterior teeth . 
f. Baseline mean tooth  shade (V ITA Bleachedguide 3D -MASTER )  11 on the facial 
surfaces of the 4 maxillary incisors.  
5.3 Exclusion Criteria  
An individual who meets any of the following exclusion criteria will be excluded from the study:  
1. Subject who is an employee of the investigational site, either directly involved in the 
conduct of the study or a member of their immediate family; or an employee of the 
investigational site otherwise supervised by [CONTACT_093]; or a n employee of the 
sponsor  directly involved in the conduct of the study or a member of their immediate 
family.  
2. Subject who has participated in other studies (i ncluding non -medicinal studies) involving 
investigational product(s) within 30 days of study entry and/or during study participation  
or who has pr eviously been enrolled in this study.  
3. Subject with , in the opi[INVESTIGATOR_1068],  an acute or 
chronic medical or psychiatric condition or laboratory abnormality that may increase the 
risk associated with study participation or study  product administration or may interfere 
with the interpretation of study results and, in the ju dgment of the investigator or 
medically qualified designee, would make the subject inappropriate for entry into this 
study.  
4. Subject who is pregnant (self -reported) or intending to become pregnant during  the study . 
5. Subject who is breastfeeding.  
6. Subject with  known or suspected intolerance or hypersensitivity to the study products  or 
any of their stated ingredients (or closely related compounds).  
7. Subject who is unwilling or , in the opi[INVESTIGATOR_1069] , unable to comply with the requirements and/or lifestyle restrictions of the study.   
8. Subject with a recent history (within the last year) of alcohol or other substance abuse.  
9. Subject with OST examination findings at Screening  which , in the opi[INVESTIGATOR_1070], could interfere with the conduct of the study  (for example, stomatitis, open 
sores, lesions, cavitied caries lesions, redness or swelling.  
10. Subject using daily oral care products and/or taking daily doses of medications/treatments 
which, in the opi[INVESTIGATOR_1071], could interfere 
with study outcomes, specifically:  
a) currently daily use of mouthwashes containing ingredients known to cause tooth 
stain (for example, chlorhexidine or cetylpyridinium chloride),  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 22 of 63 
b) past or current  use of minocycline,  
c) use of tetracycline or doxycycline within 30days of screening and/or during the 
study,  
d) medications known to cause tooth stain (for example, drugs or supplements 
containing metal ions known to increase enamel staining).  
11. Subject who has used any professionally -dispensed tooth whitening products 6 months 
prior to baseline or any over -the-counter products (including peroxide - or covarine blue -
containing dentifrice , but not other daily use whitening dentifrices ) 3 months  prior to 
baseline . 
12. Specific exclusions for assessment teeth : 
a. Non-vital tooth.  
b. Tooth with  evidence of current or recent  carious lesions . 
c. Tooth used as an abutment for fixed or p artial dentures  
d. Tooth adjacent to fixed retainers  and fixed or removable orthodontic appliances.  
e. Tooth with surface irregularities, cracked enamel, discoloration due to trauma  or 
orthodontic treatment,  tetracycline stain, restorations  or hyper -/hypoplastic areas, 
which , in the opi[INVESTIGATOR_1067], grading  of extrinsic  dental  stain  and 
tooth  shade . 
f. Tooth with a c rown or veneer.  
g. Tooth  with exposed  dentine  which,  in the opi[INVESTIGATOR_1072],  could  impact  
grading  of extrinsic  dental  stain  and tooth  shade.  
13. General oral exclusions:  
a. Generalized s evere gingivitis  or advanced periodontal diseas e; treatment of 
periodontal disease (including surgery) within 12 months of screening; scaling or root 
planning within [ADDRESS_693] who, in the opi[INVESTIGATOR_871], should not participate in the study.  
5.4 Randomization Criteria  
Subjects who satisfy the study selection criteria will be stratified will be stratified according to 
their baseline Total MLSI (A x I) (low < 45; high ≥ 45) and smoking status (smoker; non -
smoker) and randomized to study treatment .  
The two stratification factors will give rise to four strata.  
• Stratum 1:  Baseline Total MLSI (A x I) < 45, Smoker  
• Stratum 2: Baseline Total MLSI (A x I) < 45, Non -smoker  
• Stratum 3:  Baseline Total MLSI (A x I) ≥ 45, Smoker  
• Stratum 4:  Baseline Total MLSI (A x I) ≥45, Non -smoker  
5.[ADDRESS_694] subjects to remind them of lifestyle restrictions and approaching scheduled 
visits. 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 23 of 63 
5.5.1  Oral Hygiene Restrictions  
• Visit 1 onwards:  Eligible s ubjects will not be permitted to use chewing gum from 
screening to the end of the study . 
• Visits 2, 3 & 4:  Subjects will abstain from all oral hygiene procedures (including tooth 
brushing) for at least 6 hours  prior to and during their clinical/instrumental 
assessment visits . 
• Visit 1 onwards : Subjects should not use any other oral care products (for example, 
dentifrice s, toothbrushes, oral rinses, tongue cleaners, whitening/bleaching products,  
interdental cleaning products) than those provided during the study .  
Dental floss can be used to remove impacted food  from the anterior teeth; subjects 
may floss posterior teeth provided they do not abut an assessment tooth .  
5.5.2  Dietary Restrictions  
• Visits 2, 3 & 4:  Subjects will abstain from eating and drinking (with the exception of 
small amounts of water required for taking medication) for at least 2 hours  prior to 
and during their clinical/instrumental assessment visits.  
5.5.3  Use of Cosmetics  
• Visits 2, 3 & 4:  Subjects will refrain from applying  lipstick or colored lip coverings  
prior to and during their clinical/instrumental assessment visits . 
5.5.[ADDRESS_695] Restrictions  
• Visit 1 onwards:  Subjects will not be permitted to use chewing tobacco from 
screening to the end of  the study.  
• Visits 1-4: Subjects will not be permitted to smoke, vape or use tobacco products 
during their scheduled visits to the study site.  
5.5.5  Medication and Treatment Restrictions  
• Visits 1 -4: Subjects will be asked to delay elective dental treatment (for example, 
dental prophylaxis) for the duration of the study. They will be required to inform site 
staff of any emergency treatment they receive during the study . 
• Visits 3 & 4:  Subjects will be asked to inform site staff of changes to their 
medications/treat ments for the duration of the study. Should a subject commence a 
course of medication which, in the opi[INVESTIGATOR_1069], could impact study  outcomes, the subject may be withdrawn.   
5.5.6  Contraception  
There are no contrace ption requirements for subjects participating in  this study.  At each visit, 
female  subjects  of child -bearing potential should verbally confirm they are not currently 
pregnant or planning to become pregnant.  
5.6 Screen Failures  
Screen failures are defined as s ubjects who consent to participate in the clinical study but are 
not subsequently randomized.  To ensure transparent reporting of screen failure subjects, a 
minimal set of screen failure information will  be collected,  includ ing demography, reason for 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 24 of 63 
screen  failure (e.g. withdrawal of consent), eligibility criteria, any protocol deviations and any 
adverse events or incidents as applicable.  
Individuals who do not meet the criteria for participation in this study (screen failure) may not  
be re -screened.  
5.7 Spons or’s Qualified Medical Personnel  
Contact [CONTACT_1133]'s appropriately qualified medical/dental personnel for the 
study is documented in the  Study Contact [CONTACT_1134].  
The contact [CONTACT_1135]/ dental questions 
or problems in the event that the established communication pathways between the study site 
and the sponsor’s study team are not available.  
The contact [CONTACT_1136].  To facilitate access to 
appropriately qualified medical/dental personnel on study -related medical/dental questions or 
problems, subjects will be provided with a contact [CONTACT_1137].   The contact [CONTACT_1138], as a 
minimu m, protocol identifiers, the subject’s study identification number, contact [CONTACT_1139], and contact [CONTACT_1140] a medical question or problem identified by a healthcare  professional other than the 
investigator.  
5.8 Clinical Examiner  Qualifications  
Clinical examiner (s) involved in the screening, safety and efficacy assessments will be 
appropriately qualified dental professionals, registered to practice in the US.  
Oral exami nations to determine subject eligibility and to monitor the safety /performance of 
study products will be performed by [CONTACT_1141](s), with prior 
relevant clinical experience.  Clinical  examiner(s) will also be experienced in use of the VITA 
EasyShade  instrument for intra -oral measurement of tooth shade.  
6 INVESTIGATIONAL/STUDY PRODUCTS  
6.1 Investigational/Study Product Supplies  
The following study products will be supplied by [CONTACT_1142] ’s Clinical Supplies Group.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 25 of 63 
Table 6-1 Investigational/Study Product Supplies  
Product 
Description  Experimental  
Dentifrices  Reference  
Dentifrice  
5% KNO 3 dentifrice 
with 1% alum ina and 
5% STP  5% KNO 3 dentifrice 
with 1% alumina,  
5% STP and 2%  high 
cleaning silica  Regular Fluoride 
Dentifrice  
Product Name  N/A N/A Aquafresh Cavity 
Protection  
(US market)  
Fluoride 
Content  0.2542% NaF (1100 ppm fluoride)  
Pack Design  One carton containing 2 tubes of dentifrice  
Dispensing 
Details  Visit 2 (Baseline): 2 cartons ; Visit 3 (Week 4): [ADDRESS_696] Master 
Formulation 
Code (MFC)     
Dose/ Product 
Application  Subjects will dose the toothbrush provided with a strip of dentifrice  
(a full brush head) on each brushing occasion  
Route of 
Administration  Topi[INVESTIGATOR_1073] (morning and evening) for [ADDRESS_697] to be returned to the sponsor.  
 
The following su ndry items  will be supplied by [CONTACT_456] ’s Global Clinical Supplies Group.  
Table 6-2 Sundry Items  
Item Pack Design  Dispensing 
Details  Return/Disposal Details  
Used Samples  Unused 
Samples  
Parodontax Complete 
Protection  Soft-Bristled 
Toothbrush (US market ) Individual 
toothbrush in 
commercial pack  Visit 2:  
1 brush  
Visit 3 :  
1 brush  Destroy at site 
using site disposal 
procedures  Return  
to 
sponsor  
Countdown Timer  Individual 
toothbrush in 
commercial pack  At V isit 2:  
[ADDRESS_698] to keep or 
destroy at site 
using site disposal 
procedures  Return  
to 
sponsor  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI
CCI
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_699]/study supplies for the accountability checks 
and subsequent destruction which will be provided by [CONTACT_1143].  
6.1.1  Medical Devices  
The toothbrushes to be used in this study are medical devices . 
6.1.2  Dosage Form and Packaging  
The study products are dentifrices, intended for topi[INVESTIGATOR_1064], and will be applied by 
[CONTACT_1144] a manual toothbrush . 
The experimental dentifrices will be man ufactured and filled into plain white tubes by [CONTACT_103]; the reference dentifrice will be supplied in its commercial pack. All study dentifrices 
will be overwrapped in white vinyl (to mask their identity and obscure the branding of the 
marketed product)  with a study label affixed. The content of the product labels will be in 
accordance with all applicable regulatory requirements and will be the responsibility of the 
sponsor’s Global Clinical  Supplies Group. Each study label will contain, but not be limit ed to, 
protocol number, directions for use and storage requirements.  
Each subject  will receive sufficient tubes of their  assigned study dentifrice  for usage during the 
8-week treatment period. Sundry items will be supplied in their  commercial packaging fo r 
dispensing by [CONTACT_1145] 6.[ADDRESS_700], by [CONTACT_1146].   These staff members will 
not be involved in any safety/product performance assessments  or any other aspect of the study 
that could be influenced by [CONTACT_1147] a subject has been assigned to. An 
additional member of the site staff will verify the dispensing  procedure has been completed 
accurately for each subject.  
6.[ADDRESS_701] be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the 
labeled storage conditions w ith access limited to the authorized site staff only.  
Subjects will be instructed to self -administer their assigned study dentifrice according to the 
usage instructions provided to the subject.  Additionally, subjects will undergo supervised 
brushing at Vi sits 2 -4 to ensure compliance with brushing instructions.   The reference dentifrice 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 27 of 63 
is commercially available and the application instructions described in this protocol are 
consistent with it’s label instructions.  The two experimental dentifrices are int ended for 
commercialization and the application instructions here are consistent with the intended label 
instructions.  
To help ensure subjects understand the amount of dentifrice  they should use each time they 
brush , brushing  instructions  and diary complet ion requirements : 
• staff will demonstrate dispensing a full ribbon of dentifrice  along the length of the  
toothbrush head to each randomized  subject and supervise their first brushing with study 
dentifrice and  diary completion at the end of the baseline  visit (Visit  2), after all clinical 
assessments have been completed.  
• staff will supervise a brushing with study dentifrice and diary completion at the end of  
the Week 4 visit (Visit 3), after all clinical assessments have  been completed.  
On-site administration  of study products will also be recorded in the CRF.  
Instructions on usage of the study products are detailed in the Section 15.[ADDRESS_702] usage  errors may result, in this study, from the administration or 
consumption of:  
• the wrong product,  
• by [CONTACT_1148],  
• at the wrong time,  
• or at the wrong dosage.  
Such errors occurring to a study subject are to be captured in the CRF.  In the event of a product 
usage  error, the sponsor should be notified immediately and under no circumstance should 
this exceed [ADDRESS_703] usage  errors are reportable irrespecti ve of the presence of an associated AE, including:  
• Usage  errors involving subject exposure to any of the study products;  
• Potential product  errors or uses outside of what is foreseen in the protocol that do or 
do not involve the participating subject.  
If a study product usage  error is accompanied by [CONTACT_1149], as determined by [CONTACT_093], the 
usage  error and, any associated adverse event(s) are to be captured in the CRF AE form.  
6.2.[ADDRESS_704] at an amount higher than 
specified in the protocol.  
Overdose is not likely to occur in this study.  
Overdose per se is not an AE. However, any clinical sequelae of an overdose should be reported 
as an AE (and serious adverse event (SAE), if appropriate).  For reporting, follow the AE and 
SAE reporting instructions.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 28 of 63 
6.3 Investigational/Study Product Storage   
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study products received and any di screpancies are reported and 
resolved before use according to the supplied shippi[INVESTIGATOR_1074].  
The investigator, or designee, will ensure that all study products are stored in a secured , 
environmentally monitored (manual or automated)  area with control led access (authorized site 
staff only) in accordance with the labeled storage conditions and Clinical Study Supplies 
Checklist , and in accordance with applicable regulatory requirements.  
Site systems must be capable of measuring and documenting (for exam ple, via a log), at a 
minimum, daily minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated, and/or room -temperature products).  This should be 
captured from the time of first product receipt througho ut the study.  Even for continuous 
monitoring systems, a log or site procedure that ensures active daily evaluation for excursions 
should be available.  The operation of the temperature -monitoring device and storage unit (for 
example, refrigerator), as app licable, should be regularly inspected to ensure it is maintained in 
working order.  
Any excursions from the product -label storage conditions should be reported to appropriate site 
staff upon discovery and communicated to sponsor as soon as possible.  The site should actively 
pursue options for returning the product to the storage conditions as described in the labeling, 
as soon as possible.  Excursions from the storage requirements, including any actions taken, 
must be documented as a protocol deviation an d reported to the sponsor.  
Once an excursion is identified, the affected product (or products) must be quarantined and not 
used until the sponsor provides documentation of permission to use. Use of any of the affected 
product(s) prior to sponsor approval w ill be considered a protocol deviation.   
Site staff will instruct subjects on the proper storage requirements for all take -home products.  
6.[ADDRESS_705] supplies. All study products will be accounted for using the 
investigational/study product accountability form/record. The investigator is resp onsible for 
study product accountability, reconciliation, and record maintenance.  
Subjects should return their used and unused study products to the clinical site at Visits [ADDRESS_706] return will be documented.   Subjects will 
complete diaries to detail their usage of study products which will be used to monitor usage  
compliance.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_707] acc ountability will be performed by [CONTACT_1150].  
6.4.1  Destruction of Investigational/Study Product Supplies  
At the end of the study, the Principal Investigator [INVESTIGATOR_1075], and a 
representative  of the sponsor  (study monitor) will inventory all used and unused study products 
and sundry items.  The study product accountability record for returned study products will then 
be completed. All study product (used and unused) for this clinical study wil l be returned for 
destruction to the sponsor ’s Clinical Supplies Department or designated vendor using the return 
instructions provided. Detailed instructions for the return of study product/study supplies for 
the accountability checks and subsequent destr uction will be provided by [CONTACT_1151].  
6.5 Blinding and Allocation/Randomization  
All subjects will be centrally randomized to one of the three study products using an Interactive 
Response Technology (IRT). Be fore the study is initiated, training, login information and 
directions for the IRT will be provided. Study products will be dispensed according to the 
instruction received through the IRT at the appropriate study visits.  
Returned study products should not  be re -dispensed to any subject.  
The investigator’s knowledge of the product allocation should not influence the decision to 
enroll a subject or affect the order in which subjects are enrolled.  
While this  study is described as examiner -blind (the clinical examiner (s) performing the 
efficacy assessments will be blinded to the product received).  To ensure the examiner (s) 
remains blinded throughout the study,  the examiner (s) will not be permitted in any area where 
study product is stored,  dispensed, or in use  staff involved in the preparation and dispensing of 
study products will work in a separate area , and s ubjects will be instructed not to remove study 
products from the opaque bags provided/cartons outside of the dispensing room, while at the 
study site. Di spensing staff will not be involved in any efficacy/safety assessment procedures 
during the study.  
Site staff, study statistician (s), data management staff  and other  employees of the sponsor and 
vendors acting on behalf of the sponsor, who may influence  study outcomes will be blinded to 
the product allocation .   
Prior to randomization, subjects will be stratified on their baseline MLSI score and smoking 
status as detailed in Section 5.[ADDRESS_708]’s product assignment is warranted. Subject safety must always be the first consideration 
in making such a determination. If the investigator decides that unblinding is warrante d, the 
investigator should make every effort to contact [CONTACT_1152] a subject’s 
product assignment unless this could delay emergency treatment of the subject.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_709]’s product assignment is unblinded, the sponsor must be notified within [ADDRESS_710] ( IRB) if the blind is broken.  
6.[ADDRESS_711] usage requirements :  
• First use of their assigned study dentifrice will be carried out under supervision at the 
study site at the end of the baseline visit ( Visit 2 ); study  staff will demonstrate the correct 
amount of dentifrice to dispense and how to use the timer to ensure a 2 -minute b rushing 
time. A further supervised brushing will be carried out at the study site at the end of  
Week 4 procedures ( Visit 3 ). 
• Subjects will be provided with a diary at baseline  (Visit 2) and Week 4  (Visit 3) to record 
each completed brushing with study prod uct. 
• Subjects will attend each study visit with all tubes of dentifrice  provided (used and 
unused) for a visual check of product usage, and with their completed diary for review 
by [CONTACT_464].  Any suspected over or under use, the number of any missed or a dditional 
brushings will be documented as deviations in the CRF ; subjects will be re -instructed in 
the correct use of product and diary completion, as required  
• Subjects will also use the diary to note any issues with their study product, any oral 
problems,  illnesses and new medications/ treatments.  Details relevant to safety or 
efficacy should be reviewed by [CONTACT_093] (or suitably qualified designee) and 
transcribed to the CRF , as appropriate ; AEs must  be documented in the CRF.  
The number of any mis sed or additional applications or doses will be captured as protocol 
deviations. Subjects will be re -instructed in the correct usage requirements and diary completion 
as needed.  
A record of the number of dentifrice tubes  dispensed to and taken by [CONTACT_1153]. Intervention start 
and stop dates, including dates for intervention delays and/or dose reductions will also be 
recorded in the CRF.  
6.8 Concomitant Medication/Treatment(s)  
Any medications, treatments or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) taken during the study, from signing the informed consent, 
must be recorded in the CRF with indication, reason for use, unit dose, daily dose, and start and 
stop dates of administration.  All subjects will be questioned about medications/treatments at 
each site visit.  
Medication/treatments taken [ADDRESS_712] app lication will be documented as a prior medication/treatment.  
Medications/treatments taken after first study product application will be documented as 
concomitant medication/treatments.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_713] DISCONTINUATION/WITH DRAWAL  
7.[ADDRESS_714] Discontinuation/Withdrawal  
A subject may withdraw from the study at any time at their own request or may be withdrawn 
at any time at the discretion of the investigator or sponsor for safety, behavioral reasons, or the 
inability of the subje ct to comply with the protocol -required schedule of study visits or 
procedures.   
The following circumstances require discontinuation of study product and/or premature subject 
withdrawal:  
• Protocol violation that may impact the subject’s safety  
• Withdrawal o f informed consent  
• Subject lost to follow -up  
• Unblinding of the subject  
• Pregnancy  
If a subject is discontinued or prematurely withdraws from the study, the reason(s) for 
discontinuation or withdrawal and the associated date must be documented in the relev ant 
section(s) of the CRF.  
7.[ADDRESS_715] wishes 
to and/or should continue in the study.  
A subject will be considered lost to follow up if they repeatedly fail to return for scheduled 
visits and is unable to be contact[CONTACT_1154]. Before a subject is deemed lost to follow 
up, the investigator or designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_716]’s last known maili ng 
address or local equivalent methods). These contact [CONTACT_1156]. If contact 
[CONTACT_1157], the investigator should inquire about the reason for withdrawal, request 
that the subject return all products provided  and, if approp riate, request that the subject return 
for a final visit and follow -up with the subject regarding any unresolved adverse events (AEs).  
Final safety assessments may be carried out when the subject returns to the study site, at the 
investigator’s discretion,  which could include an oral examination.  
Should the subject continue to be unreachable, they will be considered to have withdrawn from 
the study and lost to follow up.  
Lack of completion of all or any of the early termination procedures will not be viewe d as 
protocol deviations so long as the subject’s safety was preserved.  
If the subject withdraws from the study and withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collect ed.  The sponsor may retain and continue to use any data collected before such 
withdrawal of consent.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_717].  
8.1 Visit 1/Screening  
Screening procedures will be conducted by [CONTACT_737], or suitably qualified designee.  
The following screening procedures will be completed, in the following order (wherever 
possible), and the findings recorded in the CRF:  
 
1. Informed Consent  
2. Demographics  
3. Review of medical history (including smoking/tobacco use status) and prior/concomitant 
medica tion/treatment  
4. Full OST and OHT examinations  
5. Review of the inclusion/exclusion criteria  
6. Subject eligibility  
 
8.1.1  Screening Procedures  
[IP_ADDRESS]  Informed Consent  
The investigator, or designee, must obtain informed consent from each subject participating in 
this study af ter adequate explanation of the aims, methods, objectives, and potential hazards of 
the study. An ingredients listing for the study dentifrices will be provided to each subject during 
the consent process to enable them to confirm  they are not aware of any allergy or 
hypersensitivity to any of the ingredients listed.   Two copi[INVESTIGATOR_1076] (ICF) 
will be signed and dated by [CONTACT_423], the subject will retain one copy and the other will be 
kept at site.  
The investigator, or designee, must a lso explain to the subjects that they are completely free to 
refuse to enter the study or to withdraw from it at any time.  Appropriate forms for documenting 
a signed and dated consent will be provided by [CONTACT_1158] . 
The inve stigator, or designee, should sign and date each copy of the ICF to confirm that the 
consent process was completed correctly after the subject has signed.   
The time the subject signed the ICF will be captured as this is the point from  which all AEs will 
be capture d. The date and time of consent will be recorded  in the CRF.  
If, during a subject’s participation in the study, any new information becomes available that 
may affect the subject’s willingness to participate in the study, each ongoing subject shoul d 
receive a copy of this new information and be re -consented into the study. Each subject should 
be provided with a copy of the signed and dated amended consent form. The date of re -consent 
will be recorded on the CRF.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_718] is confirmed 
eligible by [CONTACT_093] (or designee) to participate in the study the subject is considered 
enrolled  in the study.  
[IP_ADDRESS]  Demographics  
The following demographic information will be recorded in the CRF: year of birth, gender and 
race.  Ethnicity and race of subjects will be recorded in accordance with FDA Guidance  (US 
FDA, 2005 ). 
[IP_ADDRESS]  Medical History and Prior Medication/Treatment  
Details of relevant medical and surgical history (in the last y ear), including allergies or drug 
sensitivity, will be documented in the CRF.  
Prior medications/treatments, including prescription and non -prescription drugs, dietary 
supplements and herbal remedies, taken in the last 28 days and prior to signing the infor med 
consent form, will be documented in the CRF.  
[IP_ADDRESS]  Oral Examinations  
Following r eview of the oral care products the subject is currently using (subject -reported 
product  names) to confirm they do not contain any  ingredients that could interfere with study 
outcomes , the clinical examiner(s) will perform the following examinations/assessments.  
• OST examination.  
• OHT examination.  
• Confirm eligibility of the anterior teeth against the dentition exclusions  described in 
Section 5.3 . 
Oral examinations/assessments should only be performed by [CONTACT_1159](s) as 
described in  Section 5.[ADDRESS_719] flow, clinical assessments may be recorded on a paper source document 
and later transcribed into the CRF.   
[IP_ADDRESS]  Inclusion/Exclusion Criteria  
Inclusion and exclusion criteria information will be documented in the CRF.  
[IP_ADDRESS]  Subject Eligibility  
The investigator and/or medically qualified designee will review the inclusion/exclusion criteria, 
medical history, prior and current medications /treatments and the findings of the oral 
examinations  to confirm subject eligibility to participate in the clinical trial. This will be 
documented in the CRF.  
To prepare for study par ticipation, subjects will be instructed in the Lifestyle Guidelines  and 
any Concomitant Medication/Treatment(s)  requirements of the protocol.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 34 of 63 
8.2 Study Period  
8.2.1  Visit 2/Day 0 - Baselin e  
Procedures will be conducted by [CONTACT_737], or suitably qualified designee.  
Subjects will undergo, in the following order (wherever possible) . 
 
1. MLSI is assessed on the facial surfaces of the six maxillary anterior teeth and six 
mandibular anterior  teeth (tooth numbers 6 -11 and 22 -27), and the lingual surfaces of the 
six mandibular anterior teeth (tooth numbers 22 -27), including a repeat assessment if 
required.   At the examiner’s discretion, the examiner my use floss and/or a wetted 
toothbrush to re move debris from the teeth prior to the assessment if required.  
2. Clinical assessment of t ooth shade  is performed  on the facial surfaces of the central and 
lateral maxillary incisors (tooth numbers 7 -10) through use of the V ITA Bleachedguide 
3D-MASTER instru ment including a repeat assessment if required.  
3. Tooth color is assessed through use of the VITA Easy Shade instrument.  
4. Review of the inclusion/exclusion criteria.  
5. Subject eligibility assessed.   Subjects who do not meet the criteria for participation will be  
discontinued.  
6. Qualifying s ubjects will be stratified and randomized to treatment group s. 
7. Study products will be dispensed, including sundry items, and diary.   
8. Instruct subject in product usage requirements/diary completion and demonstrate 
dispensing ribbon of dentifrice on to toothbrush head; supervise first brushing and first 
diary entry.  
9. AEs and incidents recorded.  
Randomized subjects will be appointed to attend the study site for their Week [ADDRESS_720] flow, clinical and instrumental assessments may be recorded on a paper 
source document and later transcribed into the CRF.   
 
8.2.2  Visit 3/Week 4  (Day 28 ± 3) 
Procedures will be conducted by [CONTACT_737], or suitably qualified designee.  
Subjects will undergo, in the following  order (wherever possible), and findings  recorded in the 
CRF : 
 
1. Changes in concomitant medication or non -drug treatments/procedures will be 
documented.  
2. Spontaneous reporting of adverse events and those elicited by [CONTACT_1160] a non -leadin g question such as “How do you feel?” will be assessed.  
3. Subject will return study products and diary for visual inspection to evaluate product 
compliance  and adherence to protocol .  Subject continuance in the study confirmed.  
4. Subject undergoes an OST exami nation.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 35 of 63 
5. MLSI is assessed on the facial surfaces of the six maxillary anterior teeth and six 
mandibular anterior teeth (tooth numbers 6 -11 and 22 -27), and the lingual surfaces of the 
six mandibular anterior teeth (tooth numbers 22 -27), including a repeat as sessment if 
required.   At the examiner’s discretion, the examiner my use floss and/or a wetted 
toothbrush to remove debris from the teeth prior to the assessment if required.  
6. Clinical assessment of t ooth shade  is performed  on the facial surfaces of the cen tral and 
lateral maxillary incisors (tooth numbers 7 -10) through use of the V ITA Bleachedguide 
3D-MASTER instrument including a repeat assessment if required.  
7. Tooth color is assessed through use of the VITA Easy Shade instrument.  
8. Resupply of allocated s tudy products will be dispensed, including sundry items, and diary.  
9. Re-instruct subject in product usage requirements/diary completion; supervise on -site 
brushing and diary entry.  
10. AEs and incidents recorded.  
Subjects will be appointed to attend the study site for their Week [ADDRESS_721] flow, clinical and instrumental assessments may be recorded on a paper 
source doc ument  and later transcribed into the CRF.   
 
8.2.3  Visit 4 /Week 8  (Day 56 ± 3) 
Procedures will be conducted by [CONTACT_737], or suitably qualified designee.  
Subjects will undergo, in the following order (wherever possible) . 
 
1. Changes in concomitant medication and/or non -drug treatments/procedures will be 
documented.  
2. Spontaneous reporting of adverse events and those elicited by [CONTACT_1160] a non -leading question such as “How do you feel?” will be assessed.  
3. Subject will return study products and diary for visual inspection to evaluate product 
compliance  and adherence to protocol .  Subject continuance in the study confirmed.  
4. Subject undergoes OST and OHT examinations.  
5. MLSI is assessed on the facial surfaces of th e six maxillary anterior teeth and six 
mandibular anterior teeth (tooth numbers 6 -11 and 22 -27), and the lingual surfaces of the 
six mandibular anterior teeth (tooth numbers 22 -27), including a repeat assessment if 
required.   At the examiner’s discretion, the examiner my use floss and/or a wetted 
toothbrush to remove debris from the teeth prior to the assessment if required.  
6. Clinical assessment of t ooth shade  is performed  on the facial surfaces of the central and 
lateral maxillary incisors (tooth numbers 7 -10) through use of the V ITA Bleachedguide 
3D-MASTER instrument including a repeat assessment if required.  
7. Tooth color is assessed through use of the VITA Easy Shade instrument.  
8. AEs and incidents recorded.  
9. Study conclusion.  
To facilitate subject flow, clinic al and instrumental assessments may be recorded on a paper 
source document and later transcribed into the CRF.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 36 of 63 
8.2.4  Study Procedures  
[IP_ADDRESS]  Diary Review  
The diary should be reviewed at every visit by [CONTACT_093], or suitably qualified designee, 
and the subject. A ny subject comment captured in the diary which is considered an adverse 
event will be assessed and reported as defined in the  Adverse Event and Serious Adverse Events  
section of this protocol.   
Any additional comments  relating to medications/treatments provided in the diary will be 
reviewed by [CONTACT_1161].  
Additional and missed product applications will be considered deviatio ns from the protocol and 
will be recorded on the Deviations Log  and as a deviation in the CRF . 
[IP_ADDRESS]  Study Conclusion  
The Study Conclusion page of the CRF will be completed for all subjects whether they 
completed all study procedures or if they were discontinued  from the study early.  If the subject 
was discontinued early, at any point during the study, the primary reason for withdrawal should 
be recorded on the Study Conclusion page.  
If a subject has any clinically significant, study -related abnormalities or AEs  at the end of the 
study, the sponsor ’s medical monitor (or designated representative) should be notified,  and the 
subject may be asked to remain at the clinical site or be asked to return for a follow -up visit to 
ensure any issue is resolved or deemed not  clinically significant.  
[IP_ADDRESS]  Follow -up Visit / Phone Call  
The study site may contact a subject to follow up an AE post -study completion/withdrawal and, 
in some circumstances, request they return to the site for additional follow -up visits (final safety 
assess ments). If needed, additional clinical examinations may be carried out at such visits.  
[ADDRESS_722].  When a protocol -required assessment cannot be performed, the investigator (or 
designee) will document the reason for the missed assessment as a protocol deviation and any 
corrective and preventative actions tha t they have  taken to ensure the required processes are 
adhered to as soon as possible.  The sponsor  must be informed of any missed assessments in a 
timely manner.  The outcome of all examinations and assessments should be recorded in the 
CRF.  
9.1 Screening Ass essments  
Screening examinations and assessments will be performed by [CONTACT_1162], and in the order, defined in the Study Procedures  section of this 
protocol.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_723]’s suitability and 
eligibility for enr ollment into the study.  
9.1.[ADDRESS_724]’s suitability and 
eligibility for enrollment into the study.  
9.2 Efficacy Assessments  
The following efficacy assessments will be performed by  [CONTACT_1163] (s), at the times and in the order defined in the Study Procedures  section of this 
protocol.  
If in the opi[INVESTIGATOR_1077] a subject is between defined grades/scores, a conservative 
approach should be used to provide the final score.  The same approach should be applied 
throughout the study to ensure consistency in the grading of the scores at all timepoints.  
9.2.1  Macpherson Modification of the Lobene Stain Index (MLSI)  
Extrinsic dental stain will be assessed on the facial surfaces  of the 6 maxillary and 6 mandibular 
anterior teeth (6 -11 an d 22-27), and the lingual  surfaces of the 6 mandibular anterior teeth (22 -
27) at baseline, Week 4 and Week 8  (Visits 2 -4), using the MacPherson modification  
(Macpherson et al., 2000 ) of the Lobene stain index  (Lobene, 1968 ) (MLSI).  
All assessments should be performed by a single , trained  clinical examiner, with consistent 
lighting to standardiz e of the assessment  conditions . If required t he examiner will brush the  
subject’s  anterior teeth with a wetted toothbrush and/or floss to remove any debris which could 
impact the accuracy of the stain a ssessment .  Teeth will be air dried prior to  and during  the 
assessment  as needed.  
The facial surfaces of each assessable tooth is divided into four regions. The ‘gingival’ region 
is defined as a crescent -shaped band, approximately [ADDRESS_725] of the interdental papi[INVESTIGATOR_1078]. The ‘body’ 
of the tooth is then sub -divided into three regions on the facial surfaces.  
 
The facial and lingual surfaces of each assessable tooth wil l be divided into 2 regions, with a 
total of 4 sites per tooth surface ( Figure 9 -1). 
• Gingival Region : Defined as a crescent -shaped band  (~ 2 mm wide ) adjacent to the free 
margin of the gingiva  and extending to the crest of the inter -dental papi[INVESTIGATOR_1079]  (1 site) .  
• Body Region : The remainder of  the tooth surface  (the body)  is further  sub-divided into 3 
sites.  
• Distal facial, body facial , mesial facial  sites 
• Distal lingual, body lingual , mesial lingual sites 
 
 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 38 of 63 
Figure 9-1 MLSI Assessment  Sites: Body (B), Gingival (G), Mesial (M) , Distal (D)  
 
 
Area (A) and intensity (I) of extrinsic dental stain is scored separately for the four ‘gingival’ 
and ‘body’ sites, as follows.  
 
Score  Area  Intensity  
[ADDRESS_726] of region  Light stain  
2 Stain covering up to two  thirds of region  Moderate stain  
3 Stain covering more than two thirds of region  Heavy stain  
[IP_ADDRESS]  Repeatability of the MLSI Assessment  
To assess the repeatability of the MLSI assessments, replicate examinations will be performed 
by [CONTACT_1164].   Ten subjects will be randomly selected for repeat MLSI 
assessments at each assessment time point (Visits 2, 3 and 4), a total of 30 repeat assessments 
over the duration of the study.  Replicate assessments will be separated by a minimum of 10 
minutes (ma ximum 60 minutes) from the original assessment for a given subject and, where 
possible, separated by [CONTACT_1165].   
The scores of the initial assessment will not be visible to the examiner or scribe when the repeat 
assessment is carried out.   
9.2.2  Tooth Shade  (Color)  Assessment  
Tooth shade  (color) of  the facial surfaces of the four central and lateral maxillary incisors  (tooth 
numbers 7 -10) will be assessed  by a single , trained  clinical examiner  using the VITA 
Bleachedguide 3D -MASTER .  The arch toot h position will be parallel to the floor.   
Assessment conditions should be standardized: color corrected lighting in the range of 
5000  Kelvin ; a grey bib will be placed over the subject’s clothing ; subjects will be asked not 
to wear lipstick ; assessments  will be performed in the same room (necessary) at approximately 
the same time of day (if possible) ; outside light will be controlled by [CONTACT_1166] a windowless room.  Color determination should be made within 5 -7 seconds of starting 
an assessment to avoid eye fatigue.  
The V ITA Bleachedguide 3D-MASTER (Paravina, 2008 ) uses a value -ranked ordered scale 
from 1 (the lightest ) to 29 (the darkest ).  The shade level of each tooth surface is scored  visually 
by [CONTACT_1167].    
A single V ITA Bleachedguide will be used for all assessments throughout the study  wherever 
possible . 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 39 of 63 
[IP_ADDRESS]  Repeatability of the Tooth Colo r Shade Assessment  
To assess the repeatability of the tooth shade assessments, replicate examinations will be 
performed by [CONTACT_1168] V ITA Bleachedguide  instrument .  Ten 
subjects will be randomly selected for repeat shade  assessments  at each  assessment time point 
(Visi ts 2, 3 & 4), a total of 30 repeat shade  assessments over the duration of the study.  Replicate 
assessments will be separated by a minimum of 10 minutes (maximum 60 minutes) from the 
original assessment for a given subject and, where possible, separated by [CONTACT_1165].   
The scores of the initial assessment will not be visible to the examiner or scribe when the repeat 
assessment is carried out.  
9.2.3  VITA Easy Shade Assessment  
Tooth shade  (Bleachedguide shade) and color coordinates (L*, a*, b*)  will be measured 
instrumentally for  the facial surfaces of the four central and lateral maxillary incisors  (tooth 
numbers 7 -10) using the  VITA Easy Shade instrument. The clinical examiner will take a single 
reading from the middle section of each assessable tooth, in accordance with the manufacturer’s 
instructions.  The spectrophotometer  should be calibrated using the calibration block supplied, 
in accordance with the manufacturer’s instructions.   
The co llected data will be used to calculate  the ΔE* and WI D (del Mar Pérez et al., 2016 ) value s 
as: 
∆𝐸∗=√∆𝐿∗2+∆𝑎∗2+∆𝑏∗2 
𝑊𝐼𝐷=0.511𝐿∗−2.324𝑎∗−1.100𝑏∗ 
 
9.3 Safety and Other Assessments  
The following safety assessments will be performed by [CONTACT_1163] (s), at the times and in the order defined in the Study Procedures  section of this 
protocol.  Additionally, to help prevent COVID -19 transmissio n within the study, the 
measurement of the temperature of subjects and/or questioning of the subjects may be utilized 
at any site visit at the examiner’s discretion.  
9.3.1  Oral Soft Tissue  (OST)  Examination  
This procedure will be conducted by a qualified, experi enced clinical  examiner.  The OST 
examination will be accomplished by [CONTACT_1169] , as 
appropriate. The examination will cover  the oral labial mucosa (including lips), buccal mucosa, 
mucogingival folds, gingival muc osa, hard palate, soft palate, tonsillar area, pharyngeal area, 
tongue, sublingual area, submandibular area and salivary glands.   Findings from  the 
examination will be recorded in the CRF as either normal or abnormal, with details of any 
abnormalities. The results of the OST examination performed at screening will be used to 
determine subject eligibility. Any new OST abnormality or worsening of a pre -existing 
condition observed by [CONTACT_1170].  
Where possible, this procedure should be conducted by a single clinical examiner.   300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_727] Tissue (OHT) Examination  
This procedure should be conducted by a qualified, experienced clinical  examiner.  The OHT 
examination will be accomplished by [CONTACT_1171], using retraction aids as appropriate 
and will identify any grossly carious lesions , signs of erosive wear, enamel irregularities, tooth 
fracture, gross generalized dental caries decay, decalcification and faulty restorations. The 
presence of any implants, fixed or removable dentures, fixed or removable orthodontic 
braces/bands, fixed orthodontic retainers, full crowns or veneers will be recorded. Observations 
will be listed as eithe r absent or present, and conditions noted as present will be described in 
the eCRF. Any change observed by [CONTACT_1172] . 
The results of the  OHT examination perfor med at Screening will be used to determine subject 
eligibility.  
Where possible, this procedure should be conducted by a single clinical examiner.  
9.3.3  Pregnancy Testing  
Urine pregnancy testing of subjects of child -bearing potential is not required for this stu dy (see 
Section 4.2  for details ).  Subjects of child -bearing potential will be asked  to provide verbal 
confirmation of pregnancy status at screening (Visit 1) and to inform site staff if they find they 
are pregnant while participating in the study.  In case of a positive confirmed pregnancy, the 
subject will be withdrawn from the study . 
[ADDRESS_728] or study.  
10.1 Definition of an Adverse Event (AE)  
An AE is any untoward medical occurrence in a clinical study subject, temporally associated 
with the use of a study product including any w ashout or lead -in product (or medical device), 
whether or not considered related to the study product, including any washout or lead -in product 
(or medical device).  
NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of a study product including any washout or lead -in product (or medical device).  
Events Meeting  the AE Definition:   
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g. ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator (i.e., not related to progression of 
underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 41 of 63 
• New conditions detected or diagnosed after study product administration even though 
it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either stu dy 
product or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
• "Lack of efficacy" or  "failure of expected pharmacological action" per se will not be 
reported as an AE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of 
efficacy will be reported as AE i f they fulfill the definition of an AE.  
Events NOT  meeting the AE definition:  
• Any clinically significant abnormal laboratory findings (if applicable) or other abnormal 
safety assessments which are associated with the underlying disease, unless judged by 
[CONTACT_1173]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
conditio n.  
• Medical or surgical procedure (e.g. endoscopy, appendectomy) is not the AE. The 
condition that leads to the procedure is an AE (e.g. appendicitis).  
• Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
10.2 Definition of a Serious Adverse Event (SAE)  
A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse 
outcome is serious. If an event is not an AE per definition above, then it cannot be an SAE even 
if serious conditions are met (e.g. hospi[INVESTIGATOR_1080]/symptoms of the disease under study, 
death due to progressi on of disease).  
A serious adverse event is any untoward medical occurrence at any dose that:  
• Results in death  
• Is life -threatening   
▪ The term 'life -threatening' in the definition of 'serious' refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe;  
• Requires inpatient hospi[INVESTIGATOR_1081]   
▪ In general, hospi[INVESTIGATOR_1082] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_1083]/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious. When in doubt as to whether 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 42 of 63 
“hospi[INVESTIGATOR_059]” occurred, or was necessary, the AE should be considered 
serious.  
▪ Hospi[INVESTIGATOR_1086] r elective treatment of a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
• Results in persistent or significant disability/incapacity  
▪ The term disability means a substantial disruption of a person’s ability to conduct 
norma l life functions.  
▪ This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g. sprained ankle) which may interfere with or  
prevent everyday life functions but do not constitute a substantial disruption  
• Results in congenital anomaly/birth defect  
• Other situations:  
▪ Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situat ions such as important medical events that 
may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_1087]. These events 
should usually be considered serious.  
▪ Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result  in hospi[INVESTIGATOR_059], or development of 
drug dependency or drug abuse.  
Note:  Classification of an AE as ‘serious’ is based on the outcome of the event and is a factor 
in determining reporting requirements.  
10.[ADDRESS_729] provides consent 
to participate in the study by [CONTACT_1174] (signature) of the ICF and until [ADDRESS_730] (or last pr ocedure).  
Medical occurrences that began before obtaining informed consent will be recorded in the 
Medical History/Current Medical Conditions  section of the CRF not the AE section.  
Details recorded by [CONTACT_1175] a diary or similar document that meet t he definition of an AE 
must also be discussed with the subjects and transcribed in the AE section of the CRF.  
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed [ADDRESS_731] promptly notify the 
sponsor.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_732](s), participation in the st udy, or a study 
procedure, or that caused the subject to discontinue the study product or study.  
Spontaneous reporting of adverse events and those elicited by [CONTACT_1176]-leading such as “How do you feel” will be assessed and any AE’ s recorded in the CRF and 
reported appropriately.  
The investigator (or medically qualified designee) is to report all directly observed AEs and all 
AEs spontaneously reported by [CONTACT_1177]. In addition, each study subject will be 
questioned about AE s.  
Each AE is to be assessed to determine if it meets the criteria for a SAE.  If an SAE occurs, 
expedited reporting will follow local and international regulations, as appropriate.  
When an AE occurs, it is the responsibility of the investigator (or medic ally qualified designee) 
to review all documentation (e.g. hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.  
The investigator or site staff will then record all relevant information regarding an AE in the 
CRF and all details relating to an SAE in the paper SAE Form provided.  
It is not acceptable for the investigator (or medically qualified designee) to send photocopi[INVESTIGATOR_1089]’s medical records to the sponsor  in lieu  of completion of the AE CRF page/SAE 
form.  
There may be instances when copi[INVESTIGATOR_1090] .  In this instance, all subject identifiers, except for the subject number, will be redacted 
on the copi[INVESTIGATOR_1091] . 
The investigator (or medically qualified designee) will attempt to establish a diagnosis of the 
event based on signs, symptoms, and/or other clinical information.  The diagnosis will be the 
documented as the AE/SAE where known and not the individu al signs/symptoms. (e.g. upper 
respi[INVESTIGATOR_1092], seasonal allergy, etc. instead of runny nose).  
AEs elicited by [CONTACT_093] (or medically qualified designee) in a standard manner at the 
study visits should also be recorded in the AE section  of the CRF and/or using the SAE form 
(subject to the classification of the AE). Care will be taken not to introduce bias when 
questioning a subject about any changes in their health. Open -ended and non -leading verbal 
questioning should be used.  
10.4.[ADDRESS_733] be completed in a 
consistent manner.  For example, the same AE term should be used on both.  AEs should be 
reported using concise medical terminology on the CRF as well as on the form for collection of 
SAE information.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_734] copi[INVESTIGATOR_1093] ‘paper’ SAE form will be provided in the 
investigator study master file. Original SAE forms  will be retained in the investigator study 
master file.  
It is essential to enter the following information:  
• Protocol and subject identifiers  
• Subject demography  
• Description of events, with diagnosis if available  
• Investigator opi[INVESTIGATOR_1094] (or study procedure, if 
appropriate)  
• Criterion for seriousness.  
The following are desirable and are of particular relevance for investigator and the sponsor  
assessment of the SAE report:  
• Date of onset of AE  
• Date AE stopped, if relevant  
• Study pr oduct start date  
• Study product end date if relevant  
• Action taken in relation to the study product  
• Outcome if known  
The SAE form, completed as fully as possible, must be scanned and e -mailed to the Case 
Management Group mailbox  ), with copy to the 
appropriate  CH Study Manager, with the study number and subject number in the subject line 
of the email immediately and under no circumstance should this exceed 24 hours  after study 
site personne l learn of the event. The investigator will submit any updated SAE data to the 
sponsor, immediately and  under no circumstance should this exceed 24 hours of it being 
available.  
The initial report will be followed up with more information as relevant, or a s requested by [CONTACT_1178].  
The CH Study Manager will be responsible for forwarding the SAE form to other CH personnel 
as appropriate.  
10.5 Evaluating Adverse Events  
10.5.1  Assessment of Intensity  
The investigator or medically qualified designee will make an  assessment of intensity for each 
AE reported during the study and will assign it to one of the following categories:  
• Mild:  An event that is easily tolerated by [CONTACT_423], causing minimal discomfort and 
not interfering with everyday activities.  
• Moderate :  An event that is sufficiently discomforting to interfere with normal everyday 
activities  
• Severe:  An event that prevents normal everyday activities.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
[COMPANY_003]
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 45 of 63 
NOTE: An AE that is assessed as severe should not be confused with an SAE. Severe is a 
category utilize d for rating the intensity of an event; and both non -serious AEs and SAEs can 
be assessed as severe. For example, a headache may be severe (interferes significantly with the 
subject's usual function) but would not be classified as serious unless it met one  of the criteria 
for SAEs, listed above. An event is defined as ‘serious’ when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.  
10.5.2  Assessment of Causality  
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
For each AE (serious and non -serious), the investigator (or medically qualified designee) must  
provide an assessment of causality on the AE CRF page a nd the SAE form (subject to the 
classification of the AE). The investigator will also document in the medical notes that they 
have reviewed the AE and assessed causality, where applicable.  
A “reasonable possibility” of a relationship conveys that there ar e facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
Generally, the facts (evidence) or arguments to suggest a causal relationship should be provided.  
The investigator will use clinical judgm ent to determine the relationship and will also consult 
the Safety Statement, in the determination of their assessment.  Alternative causes, such as 
underlying disease(s), concomitant therapy, other risk factors, and the temporal relationship of 
the event to the study product will be considered and investigated.  
For each AE/SAE, the investigator must document in the medical notes that they have reviewed 
the AE/SAE and has provided an assessment of causality.  
The investigator’s assessment of causality must b e provided for all AEs (serious and non -
serious); the investigator must record the causal relationship in the CRF, as appropriate, and 
report such an assessment in accordance with the SAE reporting requirements if applicable.  
There may be situations when a n SAE has occurred, and the investigator has minimal 
information to include in the initial report to the sponsor .  However, it is very important that 
the investigator always make an assessment of causality for every event prior to the initial 
transmission of the SAE data to the sponsor . The investigator may change their opi[INVESTIGATOR_1095] -up information and send an SAE follow -up report with the updated 
causality assessment.  
10.6 Follow -up of AEs and SAEs  
After the initial AE/SAE report, th e investigator is required to proactively follow up with each 
subject and provide further information on the subject’s condition.  
All AEs (serious and non -serious) will be followed until resolution, until the condition stabilizes, 
until the event is otherw ise explained, or until the subject is lost to follow -up.   
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may be indicated or as requested by [CONTACT_1179]/or causality of the AE. This may include additional laboratory 
tests or investigations, histopathological examinations, or consultation with other health care 
professionals.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 46 of 63 
New or updated information will be recorded on the AE CRF page  and on the SAE form (subject 
to the classification of the AE).  
The investigator will submit any updated SAE data to the sponsor  within [ADDRESS_735] or study 
participation, the investigator will promptly notify the sponsor  by [CONTACT_1180] ), with copy 
to the appropriate CH Study Manager.  
The investigator will submit any updated SAE data to the sponsor  within the designated 
reporting time frames.  
10.[ADDRESS_736] under clinical investigation.  
Prompt notification of SAEs by [CONTACT_1181].  
The sponsor  will comply with country specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRB/EC and investigators.  
Both th e investigator and the sponsor will comply with all local medical device reporting 
requirements  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
(S[LOCATION_003]R) according to local regulatory requirements and sponsor policy and forwarded to 
investigators as necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information e.g. summary or listing of SAE from the sponsor will review and then file it 
along with the  Investigator’s Brochure in the investigator study master file, and will notify the 
IRB/IEC, if appropriate according to local requirements.  
10.[ADDRESS_737].  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
[COMPANY_003]
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_738] pregnancy information on the appropriate form scan and e -mail it 
to the Case Management Group mailbox ), with copy 
to the appropriate CH Study Manager. Original pregnancy information forms will be retained 
in the inv estigator study master file.  
The subject will be followed to determine the outcome of the pregnancy. Information on the 
status of the mother and infant / neonate (including concomitant medications taken by [CONTACT_1182]) will be forwarde d by [CONTACT_1183]. Generally, follow -up will be no longer than 6 to 8 weeks following the 
estimated delivery date. Any termination of the pregnancy will be reported.  
While pregnancy itself is not considered to be an AE, abnormal pregnancy outcomes (e.g. 
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are,  and 
should be recorded as an SAE.  
Any female subject who becomes pregnant while participating will be withdrawn from the study.  
10.10  Medical Device Incidents  
Both the investigator and the sponsor will comply with all local medical device reporting 
requirements . 
Medical devices are being provided by [CONTACT_1184]; the medical device in 
this study is the supplied toothbrush.  
10.10.1  Definition of an Incident  
A medical device incident is any malfunction or deterioration in the characteristics and/or 
performance of a device as well as any inadequacy in the labeling or the instructions for use 
which, directly or indirectly, might lead to or might have led to the death of a subject/user/other 
person or to a serious deterioration in their state of health.  
Not all incidents lead to death or serious deterioration in health. The nonoccurrence of such a 
result might have been due to other fortunate circumstances or to the intervention of health care 
personnel.  
It is sufficient that:  
An incident  associated with a device happened and  
• The incident  was such that, if it occurred again, might lead to death or a serious 
deterioration in health.  
• A serious deterioration in state of health can include any of the following:  
• Life-threatening illness  
• Permanent impairment of body function or permanent damage to body structure  
• Condition necessitating medical or surgical intervention to prevent one of the above  
• Fetal distress, fetal death, or any congenital abnormality or birth defects  
Examples of incidents:  
• A subject, user, ca regiver, or healthcare professional is injured as a result of a medical 
device failure or its misuse.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
[COMPANY_003]
[COMPANY_003]
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 48 of 63 
• A subject’s study treatment is interrupted or compromised by a medical device 
failure.  
• A misdiagnosis due to medical device failure leads to inappropriate  treatment.  
• A subject’s health deteriorates due to medical device failure.  
10.[ADDRESS_739]'s 
medical records, if in accordance with the investigator's normal clinical practice, and on the 
appropriate Incident Report Form.  In addition, for incidents fulfilling the definition of an AE 
(serious and non -serious), the appropriate AE CRF page and SAE form will be completed and 
reported as per the AE and SAE reporting sections.  
The Incident Report Form will be completed as thorou ghly as possible and signed by [CONTACT_1185] .  It is very important that the investigator describes 
any corrective or remedial actions taken to prevent recurrence of the incident.  
The completed Incident Report Form shou ld be scanned and emailed to the Case Management 
Group mailbox ), with copy to the appropriate  CH 
Study Manager,  with the study number and subject number in the subject line of the emai l 
immediately and under no circumstance should this exceed [ADDRESS_740] the procedure to report an SAE.  The original Incident Report Form will be retained in 
the investigator study master file.  
The initial report will be followed up with more information as relevant, or as requested by [CONTACT_1178].  
The investigator will follow the following directions regarding the reporting of a device failure 
(malfunction):  
• Notify the sponsor  immediately (by [CONTACT_1186]).  
• Schedule the subject to return to the site promptly to return the failed device.  
• Record any incidents on the CRF and Incident Report Form following instructions given 
in the section above.  
• For any incident/malfunction occurring with a medical device (including those that are 
part of combination products) su pplied by [CONTACT_456] , return the failed device to the 
sponsor as soon as possible, including documentation of the details of the failure.  
• For any incident/malfunction occurring with a medical device (including those that are 
part of combination products) supplied by [CONTACT_1187], report the incident to the 
device manufacturer and follow the manufacturer instructions for the return of the failed 
device (whilst keepi[INVESTIGATOR_1096]).  
10.[ADDRESS_741] or are 
withdrawn from the study.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
[COMPANY_003]
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 49 of 63 
The investigator is responsible for ensuring that follow -up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the incident.  
New or updated information will be recorded on the originally completed Incident Report form 
with all changes signed and dated by [CONTACT_1188]. 
10.13  Regulatory Reporting Requirements for Medical Device Incidents  
To fulfill regulatory reporting obligations worldwide, the investigator is responsible for the 
detection and documentation of events meeting the definitions of incident or malfunction that 
occur during all periods of the study in which the medical device is used.  
The investigator will promptly report all incidents occurring with any medical device provided 
for use in the study in order for the sponsor to fulfill the legal responsibility to notify appropriate 
regulatory authorities and other entities about certain safety information relating to medical 
devices being used in clinical studies.  
The investigator, or responsible person according to local requirements (e.g. the head of the 
medical institution), will comply with the applicable local regulatory requirements relating to 
the reporting of incidents to the IRB/IEC.  
[ADDRESS_742] data will be entered into an electronic CRF (eCRF), using a validated 
system. Data relating to SAEs, pregnancy and incidents will also be collected on paper forms . 
The investig ator is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].  
The source documents (e.g. hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, 
memoranda, subject diaries, questionnai res, evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, microfiches, photographic negatives, microfilm or 
magnetic media, x -rays, subject files and records kept at the pharmacy, at the laboratory and at 
the medico -technical departments involved in the clinical study) which contain the source of 
data recorded in the CRF should be specified.  The CRF and or diary  can be used as a source 
document at the discretion of data management.  
Each subject will be assigned and identified by a unique Screening Subject Number. Any 
reference made to an individual subject within the study must be done using their unique 
Screening Subject Number.  
11.[ADDRESS_743] who has given informed consent/assent the CRF must be completed and signed 
by [CONTACT_079] (or authorized designee) to certify that the da ta are complete and 
correct.  The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_744] the privacy of subjects, no Personal Information (PI) (including the subject's name 
[CONTACT_1218]) is to be recorded in the CRF or as part of the query text.  
All CRF pages should be completed during a subject assessment when the CRF has been 
designated as the source.  Data that is sourced elsewhere should be entered into the  CRF in an 
agreed upon timeframe between the Investigator and sponsor .   
The sponsor  will obtain and retain all CRFs and associated study data as applicable at the 
completion of the study.  
11.2 Data Handling  
Documentation of all data management activities shou ld allow step -by-step retrospective 
assessment of data quality and study performance.  
Any changes or corrections to data will be performed in the Electronic Data Capture (EDC) 
System, and it will include rationale for changes. The EDC system has an audit trail, which will 
provide a complete record of the changes and corrections endorsed by [CONTACT_737].  
Adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA) 
and any concomitant medications terms (if applicable) using a validated medication dictionary, 
WHODrug .   
11.2.1  Data Queries  
Programmed edit checks will be generated automatically, as the data are being entered into the 
system. Reports and listings on the CRF data will also be run, in addition to the queries already 
progra mmed and generated by [CONTACT_1190], to raise manual queries as needed for site 
clarification or correction. The sponsor’s third party vendor  will raise queries as needed on 
safety data to code the terms (AEs and Drugs or concomitant medication) appropriately .  
The study monitor will perform ongoing review of the CRFs in accordance with the monitoring 
plan, to confirm that data entered into the CRF by [CONTACT_1191], 
complete, and verifiable from source documents; that the safety and ri ghts of participants are 
being protected; and that the study is being conducted in accordance with the currently approved 
protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.  
Any queries will be generated in the EDC  System to the Investigator or designee, enabling the 
errors to be addressed in parallel with Data Management review. The study monitor can also 
run reports and listings on the CRFs, to raise manual queries as needed for site clarification or 
correction.  
12 STATISTICAL CONSIDERATIONS AND DATA ANALYSES  
12.1 Sample Size Determination  
The study will be powered sufficiently ( >90%) to provide evidence of superiority for a n 
Experimental Dentifrice compared to the Reference Dentifrice for both stain removal and 
whitening  after 8 weeks under the graphical approach method (with initial two -sided alpha 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 51 of 63 
allocation of 5% for testing within each Experimental Dentifrice) to adjust for multiple 
comparisons and preserve a two -sided 10% family wise error rate as described in sectio n 12.3.  
Table 12-1 Sample Size Power by [CONTACT_1106] 5% and 2.5% Significance Levels  
with 90 Subjects per Arm  
Endpoint at  
Week 8  Assumptions  Independent  power from 
90 subjects per arm for 
each endpoint by [CONTACT_1192] -
sided significance level 
3 Power from 
graphical 
approach to 
achieve 
statistical 
significance at 
5% level  [ADDRESS_745] 
Deviation 
(SD) 5% 2.5%  
Within Experimental 
Dentifrice change from 
baseline in mean Total 
MLSI ( Area x Intensity)  1 0.6 0.4 >99.9%  >99.9%  >99.9%  
Comparison with 
Reference Dentifrice in 
change from baseline in 
mean Total MLSI  (Area  x 
Intensity ) 1 0.3 0.4 99.8%  99.7% 99.8%  
Within change from 
baseline in the mean 
VITA shade  score 2 2 2 >99.9%  >99.9%  >99.9%  
Comparison with 
Reference Dentifrice in 
change from baseline in 
the mean VITA shade  
score 2 1 2 91.5% 86.1% 90.2% 
1) Estimates of mean difference and SD were based on results from  previous [COMPANY_004]CH stud ies of similar design 
 
2) Estimates of mean difference and SD were based  on results  from a previous [COMPANY_004]CH stud y of similar design  
 Within treatment study reductions in the mean VITA shade  score  are expected to be greater in this 
study due to greater baseline V ITA shade scores and an [ADDRESS_746] size (mean difference/SD) of 0.5 is assumed.  
3) Based on carrying out a two tailed one -sample (within  Experimental Dentifrice) or two -sample (Comparison with 
Reference Dentifrice) t -test at the 5% significance level using PASS software version 19.0.1.  
4) Simulation using SAS 9.[ADDRESS_747] entirely on the mean VITA  shade  score  reduction 
comparison between Experimental and Reference Dentifrices. Simulation shows that under the 
graphical approach methodology (Section 12.3 ) and the above underlying assumptions for an 
Experimental Dentifrice, the power to show statistical significance in all 4 comparisons for that 
Experimental Dentifrice (reduction from baseline and superior reduction compared to 
Reference De ntifrice in both mean Total MLSI [Area  x Intensity ] and mean VITA shade  score ) 
is > 90%.  
Approximately 100 subjects per group (approximately 300 in total) will be randomized to 
account for  a drop-out rate of up to 10%  prior to Week 8.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_748] received. All 
assessments of safety will be based on this analysis population.  
The modified Intent -To-Treat (mITT) population will include all randomized subjects who 
complete at least one use of study product and have at least one post baseline efficacy 
assessment. This population will be b ased on the study product to which the subject was 
randomized. All assessments of efficacy will be primarily based on this analysis population.  
The per protocol (PP) population is defined as all subjects in the mITT population who have at 
least one assessm ent of efficacy considered unaffected by [CONTACT_1193].  
12.2.2  Exclusions of Data from Analysis   
Exclusion of any data from the analyses will be determined during a Blinded Data Review 
(BDR) Meeting prior to database lock. Any reasons for exclusion from an analysis population 
will be listed, if applicable.  
A PP analysis will be performed on the mean Total MLSI (Area  x Intensity ) and mean VITA 
shade score endpoints  if there is more than 10% difference in the number of subjects between 
the PP and mITT populati ons. A decision on whether a PP analysis will be performed will be 
made prior to study unblinding (release of the randomization codes).  
12.3 Statistical Analyses  
Additional details of the proposed statistical analyses will be documented in the statistical 
analy sis plan (SAP), which will be written following finalization of the protocol and prior to 
study unblinding. This section is a summary of the planned statistical analyses of the most 
important endpoints including primary and key secondary endpoints.  
12.3.1  Primary  Analyses  
The hypothesis testing of the mean Total MLSI (Area x Intensity) and mean VITA shade score 
within each Experimental Dentifrice  will employ the graphical approach shown in Figure 12.1, 
as per Bretz et al (Bretz et al., 2009 ) in order to maintain an overall two -sided familywise error  
rate at 5% within each Experimental Dentifrice  (10% overall).  
For stratification purposes, t he Total MLSI (Area x Intensity) will be derived as the sum of the 
MLSI (Area x Intensity) scores for each of evaluated regions (gingival and body) of the facial 
surfaces of each anterior tooth (4 values per assessed tooth surface) .   
For efficacy evaluation, t he mean Total MLSI (Area x Intensity) for a subject will be derived 
as the  mean of the Total MLSI (Area x Intensity) scores across all anterior teeth assessed  (facial 
surfaces of the maxillary and mandibular anterior teeth and the lingual surfaces of the 
mandibular teeth,  4 values per assessed tooth surface) . 
The mean VITA shade score for a subject will be derived as the mean of the VITA shade  scores 
across all teeth assessed.  
  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 53 of 63 
Figure  12-1 Graphical Approach Showing Allocation and Propagation of Alpha 
Between Hypotheses  Within Each Experimental Dentifrice   
 
The above hypotheses tests will be conducted based on separate Mixed Models with Repe ated 
Measures (MMRM) for the change from baseline in the mean Total MLSI ( Area x Intensity ) 
and mean VITA shade  score . Fixed effects will be included for smoking status, study product, 
visit and study product x visit interaction. The respective baseline re sult will be included as a 
covariate. Subject will be included as a repeated measure with unstructured covariance matrix. 
Kenward Rogers degrees of freedom approach will be applied. The least square means for each 
study product at week [ADDRESS_749] for < [ADDRESS_750] 
for a difference between products. The adjusted two -sided p -values and simultaneous 95% 
confidence intervals (following graphical testing approach) will be provided for all 
comparisons.  
The assumption of normality and homogeneity of variance in the MMRM will be investigated. 
In case of violation of these assumptions, a suitable nonparametric test (adjusted for the 
randomization stratification) will be performed for each comparison at week 8 and results will 
be provided to support the MMRM results.  
The mean Total MLSI ( Area x Inte nsity ) and mean VITA shade  score  values across the study 
and change from baseline will be summarised descriptively.  
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_751] comparisons for the mean Total MLSI ( Area x Intensity ) 
and mean VITA shade  score  after [ADDRESS_752] comparisons for the other secondary and exploratory 
efficacy endpoints (see Section 3 ) after 4 and 8 weeks  will be based on the same MMRM as 
used for the primary analyses (replacing the respective baseline for the endpoint as a covariate) 
and the least square means comparisons at weeks [ADDRESS_753] received.  
Safety analyses will focus on:  
• Exposure and  compliance with study product  
• Adverse Events (AEs)  
All AEs will be reviewed by [CONTACT_1194], or designee, prior to database lock 
and unblinding and will be coded using the MedDRA. During this review stage, AEs will be 
further categorize d as oral or non -oral. AEs will be regarded as ‘treatment’ emergent if they 
occur on or after the first use of study product at the Baseline visit.  
The following AEs summaries (number of distinct AEs and frequency/proportion of subjects 
affected will be p resented by [CONTACT_1195] :  
• Treatment emergent AEs  
• Treatment emergent AEs by [CONTACT_1196] (SOC)  and Preferred Term (PT) ;  
• Treatment emergent AEs by [CONTACT_1197]/Non -Oral and PT;  
• Treatment emergent treatment related AEs by [CONTACT_1197]/Non -Oral and  PT; 
• Treatment emergent treatment related serious AEs by  [CONTACT_1198];  
A listing of all AEs will be presented for all subjects in the Safety population. Separate listings 
will be presented for any deaths, serious AEs and AEs leading to study or product 
discontinuation.  
• Oral Soft Tissue and Examinations  
• Oral Hard Tissue and Examinations  
A list of medical device incidents will also be included as part of the safety analyses.  No 
specific risks or anticipated adverse device effects are  expected to be observed within this study, 
however all AEs and medical device incidents will  be assessed to evaluate the tolerability and 
safety of the treatments.  
12.3.[ADDRESS_754] and second assessments on each tooth site will be 
cross tabulated. A weighted Kappa coefficient ( κ), along with the 95% CI will be calculated 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 55 of 63 
to assess the intra -examiner reliability. Fleiss -Cohen weighted kappa will  be calculated for the 
repeatability analysis. Reliability will be deemed  
• Excellent if κ > 0.75  
• Fair to good if 0.4 ≤ κ ≤ 0.75 
• Poor if κ <0.[ADDRESS_755] Compliance and Use of Other Therapi[INVESTIGATOR_014]  
[IP_ADDRESS]  Study Product Compliance  
Number of brushings, brushing compliance (%), number of missed brushings, number of 
additiona l brushings will be summarized using descriptive statistics by [CONTACT_1199] .  
Number of brushings is defined as: [(date of Visit  N – date of Visit  2) multiplied by 2 – number 
of missing brushings + number of additional brushings].  
Brushing compliance (%) is defined as: [100 x (Number of brushings / Expected number of 
brushings)], where expected number of brushings is defined as: [(date of Visit  N – date of Visit  
2) multiplied by 2].  
[IP_ADDRESS]  Prior and Concomitant Medications  
Prior and Concomitant Medications wi ll be listed only.  
[IP_ADDRESS]  Handling of Dropouts and Missing Data  
The use of MMRM analyses account for missing data assuming a missing at random assumption, 
i.e., there is a systematic relationship between the propensity of missing values and the observed 
data, but not the missing data.  
It is therefore assumed that a su bject with missing data would have obtained a similar efficacy 
result compared to a subject using the same study product with the same smoking status and 
similar non -missing results at other timepoints (baseline and post -baseline). Sensitivity analyses 
may be added to the SAP prior to unblinding in case of high drop -out rates and/or exclusion 
from PP population.  
12.3.7  Interim Analysis  
No interim analysis is planned for this study.  
13 STUDY GOVERNANCE CONSIDERATIONS  
13.1 Quality Control  
In accordance with applicable re gulations including GCP, and the sponsor ’s procedures, the 
sponsor  or designee (i.e. third -party vendor) monitors will contact [CONTACT_1200], study requirements, and their responsibiliti es 
to satisfy regulatory, ethical, and the sponsor ’s requirements.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 56 of 63 
When reviewing data collection procedures, the discussion will include identification, 
agreement and documentation of data items for which the CRF will serve as the source 
document.  
The sponsor or designee will monitor the study and site activity to verify that the:  
• Data are authentic, accurate, and complete.  
• Safety and rights of subjects are being protected.  
• Study is conducted in accordance with the currently approved protocol and any other  
study agreements, GCP, and all applicable regulatory requirements.  
The extent and nature of monitoring will be described in a written monitoring plan on file with 
the sponsor . The investigator (or designee) agrees to allow the monitor direct access to all  
relevant documents and agrees to co -operate with the monitor to ensure that any problems 
detected in the course of these monitoring visits are resolved.  
13.[ADDRESS_756] a quality assurance assessment and/or audit of the site records, and the regulatory 
agencies may conduct a regulatory inspection at any time during or after completion of the 
study.  
In the event of an assessment, audit or inspection, the inv estigator (and institution) must agree 
to grant the advisor(s), auditor(s) and inspector(s) direct access to all relevant documents and 
to allocate their time and the time of their staff to discuss the conduct of the study, any 
findings/relevant issues and  to implement any corrective and/or preventative actions to address 
any findings/issues identified.  
The investigator(s) will notify the sponsor  or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the i nvestigator will cooperate with 
the sponsor  or its agents to prepare the study site for the inspection and will allow the sponsor  
or its agent, whenever feasible, to be present during the inspection. The investigator will 
promptly apply copi[INVESTIGATOR_1098]. Before response 
submission to the regulatory authority, the investigator will provide the sponsor  or its agents 
with an opportunity to review and comment on responses to any such findings.  
The sponsor will be ava ilable to help investigators prepare for an inspection.  
13.[ADDRESS_757]/ Ethics Committee  
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments  and informed consent documents, investigator brochure/safety statement 
(including any updates) and other relevant documents, e.g.  recruitment advertisements, if 
applicable, from the IRB/EC.  All correspondence with the IRB/EC should be retained in the 
investigator file.  Copi[INVESTIGATOR_1099]/EC approvals should be forwarded to the sponsor  prior to the 
initiation of the study, and also when subsequent amendments to the protocol are made.  
The only circumstance in which an amendment may be initiated prior to IRB/EC approval is 
where the change is necessary to eliminate apparent immediate hazards to the subjects.  In that 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_758] notify the IRB/EC and the sponsor  in writing immediately after the 
implementation.  
13.3.[ADDRESS_759] of the Study  
The stu dy will be conducted in accordance with the protocol and legal and regulatory 
requirements, as well as the general principles set forth in the International Ethical Guidelines 
for Biomedical Research Involving Human Subjects (Council for International Orga nizations 
of Medical Sciences 2002), International Ethical Guidelines for Health -Related Research 
Involving Humans (ICH, Nov 2016 ), guidelines for GCP (ICH, 1997 ), and the Declaration of 
Helsinki (World Medical Association, 2013 ).  
In addition, the study will be conducted in accordance with the protocol, the ICH guideline on 
GCP, and applicable local regulatory requirements and laws.  
13.3.[ADDRESS_760]’s numerical code to his or her actual identity.  In case of data transfer, the sponsor  
will maintain high standards of confidentiality and protection of subjects’ per sonal data 
consistent with applicable privacy laws.  
The informed consent documents must be in compliance with ICH GCP, local regulatory 
requirements, and legal requirements, including applicable privacy laws.  
The informed consent documents used during the informed consent process must be reviewed 
and approved by [CONTACT_456], approved by [CONTACT_1201]/EC before use, and available for inspection.  
The investigator must ensure that each study subject,  is fully informed about the nature and 
objectives of the study and  possible risks associated with participation.  
13.3.[ADDRESS_761] Recruitment  
Advertisements approved by [CONTACT_1202]/ECs and investigator databases may be used as recruitment 
procedures.   Use of ethics committee approved, generic, prescreening questionnaire to assess 
basic subject characteristics to determine general eligibility for this study is allowed.   This 
generic questionnaire may be used by [CONTACT_1203] a phone script and/or to review internal databases 
to identify subjects.   
The sponsor  will have an opportunity to rev iew and approve the content of any study 
recruitment materials directed to potential study subjects before such materials are used.  
13.3.[ADDRESS_762] 
research studies.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 58 of 63 
In the event of any prohibition or restriction imposed (i. e., clinical hold) by [CONTACT_1204], or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, the sponsor  should be inf ormed immediately.  
In addition, the investigator will inform the sponsor  immediately of any urgent safety measures 
taken by [CONTACT_1205], and of any 
serious breaches of this protocol or of ICH  GCP that the investigator becomes aware of.  
13.[ADDRESS_763] the opportunity 
to review the complete study results at the sponsor ’s site or other mutually -agreeable location.  
The sponsor  will also provide the investigator with the full summary of the study results.  The 
investigator is encouraged to share the summary results with the study subjects, as appropriate.  
The pr ocedures and timing for public disclosure of the results summary and for development of 
a manuscript for publication will be in accordance with the sponsor ’s Policy.  
A manuscript will be progressed for publication in the scientific literature if the result s provide 
important scientific or medical knowledge.  
13.[ADDRESS_764] maintain all site study records (except for 
those required by [CONTACT_1206]), in a safe and secure l ocation.   
The records (study/ site master file) must be maintained to allow easy and timely retrieval, when 
needed (e.g. for a sponsor  audit or regulatory inspection) and must be available for review in 
conjunction with assessment of the facility, support ing systems, and relevant site staff.  
Where permitted by [CONTACT_1207]/regulations or institutional policy, some or all of these records 
can be maintained in a format other than hard copy (e.g. microfiche, scanned, electronic); 
however, caution needs to be ex ercised before such action is taken.  
The investigator must ensure that all reproductions are legible and are a true and accurate copy 
of the original and meet accessibility and retrieval standards, including re -generating a hard 
copy, if required.  Furthe rmore, the investigator must ensure there is an acceptable back -up of 
these reproductions and that an acceptable quality control process exists for making these 
reproductions.  300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_765]’s anonymity will be maintained.  On CRFs or other 
documents submitted to the sponsor , subjects should not be identified by [CONTACT_1208], 
but by [CONTACT_1209]. The investigator should keep a separate log of subjects’ codes, 
names and addresses.  Documents not for submission to the sponsor , e.g. subjects’ written 
consent forms, should be maintained by [CONTACT_1210].  
Records and documents, including signed ICF, pertaining  to the conduct of this study must be 
retained by [CONTACT_1211], from the issue of the final 
Clinical Study Report (CSR) or equivalent summary,  unless local regulations or institutional 
policies require a longer r etention period. The minimum retention time will meet the strictest 
standard applicable to that site for the study, as dictated by [CONTACT_1212], the sponsor ’s standards/procedures, and/or institutional require ments.   
No study document should be destroyed without a prior written agreement between the sponsor  
and the investigator. The investigator must notify the sponsor  of any changes in the archival 
arrangements, including, but not limited to, archival at an o ff-site facility or transfer of 
ownership of the records in the event the investigator is no longer associated with the site.  
13.7 Conditions for Terminating the Study  
Premature termination of this study may occur because of a regulatory authority decision, 
change in opi[INVESTIGATOR_1100]/EC, or study product safety problems, or at the discretion of the 
sponsor .  In addition, the sponsor  retains the right to discontinue development of the 
experimental dentifrices at any time.  
If a study is prematurely terminated,  the sponsor  will promptly notify the investigator.  After 
notification, the investigator must promptly contact [CONTACT_1213]/ follow -up for the subjects.  As directed by [CONTACT_456] , all study materials 
must be collected and all CRF’s completed to the greatest extent possible. Where required by 
[CONTACT_1214], the sponsor  should inform the regulatory authority(ies) 
and the investigator should promptly inform the IRB/EC and provide t he IRB/EC a detailed 
written explanation of the termination or suspension.  
If the IRB/EC terminates or suspends its approval/favorable opi[INVESTIGATOR_1101] a trial, the investigator 
should promptly notify the sponsor  and provide the sponsor  with a detailed written explanation 
of the termination or suspension.  
Upon completion or premature discontinuation of the study, the sponsor ’s  monitor will conduct 
site closure activities with the investigator or site staff, as appropriate, in accordance with 
applicable regulati ons including GCP, and the sponsor ’s Standard Operating Procedures.  
14 REFERENCES  
[ADA (2020)] Home Use Tooth Bleaching Products.  
[ADA (2022)] Toothbrushes. https://www.ada.org/resources/research/science -and-research -
institute/oral -health -topi[INVESTIGATOR_1102]/toothbrushes : Extracted 26 April 2022.  
[Ash A, Mulh olland F, Burnett GR, et al. (2014)] Structural and compositional changes in the 
salivary pellicle induced upon exposure to SDS and STP. Biofouling; 30(10): 1183 -97. 
[Bretz F, Maurer W, Brannath W, et al. (2009)] A graphical approach to sequentially reject ive 
multiple test procedures. Statistics in medicine; 28(4): 586 -604. 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 60 of 63 
[del Mar Pérez M, Ghinea R, Rivas MJ, et al. (2016)] Development of a customized whiteness 
index for dentistry based on CIELAB color space. Dental Materials; 32(3): 461 -7. 
[Dozić A, Klev erlaan CJ, El ‐Zohairy A, et al. (2007)] Performance of five commercially 
available tooth color ‐measuring devices. J. Prosthodont.; 16(2): 93 -100. 
[Featherstone JD (1999)] Prevention and reversal of dental caries: role of low level fluoride. 
Community denti stry and oral epi[INVESTIGATOR_623]; 27(1): 31 -40. 
[Gillam DG (1996)] Efficacy of a potassium nitrate mouthwash in alleviating cervical dentine 
sensitivity (CDS). Journal of Clinical Periodontology; 23(11): 993 -7. 
[Gómez‐Polo C, G ómez‐Polo M, Mart ínez Vazquez De Pa rga JA, et al. (2015)] 3D 
Master Too thguide according to L*, C*, and h* coordinates. Color Research & Application; 
40(5): 518 -24. 
[ICH (1997)] GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8.  
[ICH (Nov 2016)] Topic E6 (R2) Guideline for Good Clinical Practic e. 
[Joiner A, Luo W (2017)] Tooth colour and whiteness: A review. Journal of dentistry; 67: S3 -
S10. 
[Knezovic Zlataric D, Illeš D, Alajbeg IŽ, et al. (2016)] In vivo evaluations of inter -observer 
reliability using VITA Easyshade® Advance 4.0 Dental Shade -Matching Device. Acta 
stomatologica Croatica: International journal of oral sciences and dental medicine; 50(1): 34 -
9. 
[Lippert F (2013)] An introduction to toothpaste - its purpose, history and ingredients. 
Monographs in oral science; 23: 1 -14. 
[Lobene R ( 1968)] Effect of dentifrices on tooth stains with controlled brushing. J Am Dent 
Assoc; 77: 849 -55. 
[Macpherson LM, Stephen KW, Joiner A, et al. (2000)] Comparison of a conventional and 
modified tooth stain index. J Clin Periodontol; 27(11): 854 -9. 
[Marinh o VC, Higgins J, Logan S, et al. (2003)] Fluoride toothpastes for preventing dental 
caries in children and adolescents. Cochrane database of systematic reviews; (1).  
[Milleman KR, Milleman JL, Young S, et al. (2017)] Randomized Controlled Trial to Explore 
the Effect of Experimental Low Abrasivity Dentifrices on Enamel Gloss and Smoothness, and 
the Build -up of Extrinsic Tooth Stain. J Clin Dent; 28(2): 1 -8. 
[NHS (2019)] Teeth cleaning guide https://www.nhsinform.scot/healthy -living/dental -
health/your -teeth/teeth -cleaning -guide : Extracted 26 March 2019.  
[Pader (2012)] Dentifrices',  Kirk -Othme r Encyclopedia of Chemical Technology: John Wiley 
and Sons.  
[Paravina RD (2008)] New shade guide for tooth whitening monitoring: visual assessment. J. 
Prosthet. Dent.; 99(3): 178 -84. 
[Samant A, Ma lik C, Chabra S, et al. (1977)] Gingivitis and periodontal disease in pregnancy. 
Obstetrical & Gynecological Survey; 32(3): 140 -1. 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 61 of 63 
[Samant A, Malik C, Chabra S, et al. (1976)] Gingivitis and periodontal disease in pregnancy. 
47(7): 415 -8. 
[Schiff T, Dotson  M, Cohen S, et al. (1994)] Efficacy of a dentifrice containing potassium 
nitrate, soluble pyrophosphate, PVM/MA copolymer, and sodium fluoride on dentinal 
hypersensitivity: A twelve -week clinical study. Journal of Clinical Dentistry; 5(SPEC. ISS.): 
87-92. 
[Seong J, Hall C, Young S, et al. (2017)] A randomised clinical in situ study to evaluate the 
effects of novel low abrasivity anti -sensitivity dentifrices on dentine wear. J Dent; 57: 20 -5. 
[Shellis RP, Addy M, Rees GD (2005)] In vitro studies on the effe ct of sodium 
tripolyphosphate on the interactions of stain and salivary protein with hydroxyapatite. Journal 
of Dentistry; 33(4): 313 -24. 
[Tung FF, Goldstein GR, Jang S, et al. (2002)] The repeatability of an intraoral dental 
colorimeter. J. Prosthet. Dent.; 88(6): 585 -90. 
[US FDA (2005)] GUIDANCE FOR INDUSTRY: COLLECTION OF RACE AND 
ETHNICITY DATA IN CLINICAL TRIALS.  
[Watts A, Addy M (2001)] Tooth discolouration and staining: A review of the literature. 
British Dental Journal; 190(6): 309 -16. 
[World Medical Association (2013)] Declaration of Helsinki, 64th General Assembly, 
Fortaleza.  
[Young S, Mason S, Milleman JL, et al. (2017)] A randomized clinical study to evaluate the 
effect of an ultra low abrasivity dentifrice on extrinsic stain. American Journal of Dentistry; 
30(5): [ADDRESS_766] USE  
Brush twice a d ay (morning and evening).  
Each time you brush:  
• Dispense a ribbon of toothpaste covering the length of the toothbrush head (see below 
pi[INVESTIGATOR_1103]).  Only the supplied toothbrush may be used.  
• Set your timer for 2 minute s, and then brush your teeth in your usual manner for 2 timed 
minute s. 
 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 62 of 63 
 
 
• Record each brushing  on the diary card . Note any changes to these brushing procedures 
and reasons for changes (e.g. missed brushings, extra brushings) in the ‘Comments’ 
column.  
• Record any changes in your smoking habits, health, medications (prescription and over 
the counter medications) , or treatments  on the diary card.  
• Bring your diary  card (completed and not completed) , toothpaste and toothbrush to the 
next study visit.  
 
15.[ADDRESS_767]  European Clinical Trials Database  
FDA Food and Drug Administration ([LOCATION_002])  
GCP  Good Clinical Practice  
ICH International Conference on Harmonisation  
ID identification  
IEC Independent Ethics Committee  
IRB institutional review board  
LSLV  last subject last visit  
KNO 3 Potassium nitrate  
MedDRA  medical Dictionary for Regulatory Activities  
MLSI  Modified Lobene Stain Index  
MMRM  Mixed Models with Repeated Measures  
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
[COMPANY_004]  Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300024  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 63 of 63 
Abbreviation  Term  
N/A not applicable  
PI [INVESTIGATOR_1104]  
 300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
Signature [CONTACT_1219]  300024 TMF-236430 v3.0
Signature [CONTACT_1220]-236430 v3.0Reason for signing: Approved Name: 
[CONTACT_1221]: A
Date of signature: 
[CONTACT_1222]+[PHONE_022] | Protocol  07 Sep 2022 | TMF-236430 | 3.0
[COMPANY_003]
[COMPANY_003]